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1. Introduction 
Hazardous substances are routinely released into the environment as a result of predictable 
continuous or short-term emissions from facilities and predictable process upsets or leaks.  As a 
result, the public living or working in communities surrounding industrial facilities is at risk of 
being exposed to airborne toxicants. 
Local air pollution control officers, industrial facility operators, and others have a need for clear 
guidance regarding the acute health effects of hazardous substances.  Currently there are 
numerous sources of acute exposure levels developed by various committees for application 
primarily to occupational and military settings.  However, values for acute exposure of the general 
public are of limited number and uneven quality, and focus on industrial accidents instead of 
predictable, routine, short-term emissions.  While some methods relate toxicological information 
from human data and animal experiments to acute chemical exposure, they may be based upon 
flawed or inconsistent algorithms or are not designed for the special case of predictable exposure 
of the public to airborne toxicants (Robinson and Paxman, 1992).  Furthermore, there often exist 
several different acute exposure levels for a single compound, each developed by a different 
organization.  These values may differ by more than 100-fold, which confounds prudent decisions. 
Consequently, there are few existing guidelines that reflect sound science, clearly take into 
account issues such as appropriate endpoints and uncertainties about toxicity, and focus on 
routine or predictable acute air releases. 
The National Academy of Sciences (NAS)
1 recommends that the United States Environmental 
Protection Agency (U.S.EPA) more clearly define, and in some cases change, the methods and 
assumptions used to estimate the risk of cancer and other health problems from hazardous air 
pollutants (NRC, 1994).  Specifically, NAS has endorsed the development of biologically based 
quantitative methods for assessing the effects of exposure to a chemical.  This includes 
incorporating information on mechanisms of action and variability among populations and 
between individuals that might affect susceptibility to toxic insults, such as age, lifestyle, genetic 
background, sex, and ethnicity.  NAS recognized the continued need to use default options to 
address the uncertainties of underlying mechanisms in risk assessment for populations.  NAS has 
recommended that U.S.EPA (1) explicitly identify each use of a default option in risk assessment; 
(2) clearly state the scientific and policy basis for each default option; and (3) articulate criteria for 
allowing departure from default options.  NAS has also recommended that U.S.EPA screen the 
hazardous air pollutants identified in the 1990 Clean Air Act Amendments to establish priorities 
for setting standards, identifying data gaps, and developing incentives to expedite the generation 
of data by other governmental agencies. 
The Office of Environmental Health Hazard Assessment (OEHHA) has followed the NAS 
recommendations by establishing uniform, science-based guidelines to be used in the derivation of 
acute severity levels applicable to the general public exposed routinely to hazardous substances 
released into the environment.  By investigating existing exposure values developed by other 
organizations (described below), OEHHA has been able to identify some of the data gaps and 
1 Appendix E contains a glossary of the principal acronyms used in this document. 
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inconsistencies contained in the existing guidelines.  The results of this investigation have allowed 
the development of a more rigorous and resource-intensive scientific methodology which has been 
used to calculate acute exposure levels for prioritized chemicals.  The use of benchmark dose 
methodology, described later in this document, is an example of departure from default options as 
recommended by NAS.  Better human dose-response data, for example, from improved 
workplace monitoring correlated with symptoms and more extensive epidemiologic studies, are 
needed before the departure from default approaches can be expanded to more substances. 
1.1  Objective 
The objective of this document is to present a method for deriving acute (one-hour) inhalation 
Reference Exposure Levels (RELs) for hazardous airborne substances.  The acute REL is an 
exposure that is not likely to cause adverse effects in a human population, including sensitive 
subgroups, exposed to that concentration for one hour on an intermittent basis.  These health-
based acute RELs are applicable to risk characterization of air releases, defined in Health and 
Safety Code Section 44303, as: 
“including actual or potential spilling, leaking, pumping, pouring, emitting, emptying, 
discharging, injecting, escaping, leaching, dumping, or disposing of a substance into the 
ambient air and that results from routine operation of a facility or that is predictable, 
including, but not limited to continuous and intermittent releases and predictable process 
upsets or leaks.” 
1.1.1  Definition of Reference Exposure Level (REL) 
The concentration level at or below which no adverse health effects are anticipated for a specified 
exposure duration is termed the reference exposure level (REL).  RELs are based on the most 
sensitive, relevant, adverse health effect reported in the medical and toxicological literature. 
RELs are designed to protect the most sensitive individuals in the population by the inclusion of 
margins of safety.  Since margins of safety are incorporated to address data gaps and 
uncertainties, exceeding the REL does not automatically indicate an adverse health impact. 
Figure 1 depicts the steps involved in developing RELs.  While we conduct a complete literature 
search for each chemical, in the chemical summaries in Appendix C we only describe the key 
studies used in the acute REL development. 
1.1.2  Legislative Mandate 
As defined under the Air Toxics “Hot Spots” Information and Assessment Act of 1987 (“AB 
2588” [Chapter 1252, Statutes of 1987], California Health and Safety Code Section 44300 et 
seq., as amended), a risk assessment includes a comprehensive analysis of the dispersion of 
hazardous substances in the environment, and the potential for human exposure and a quantitative 
assessment of both individual and population-wide health risks associated with those levels of 
exposure.  This document establishes a standardized procedure for generating the health based 
values (acute reference exposure levels) used for assessing acute, noncancer risks within the risk 
assessment process. 
2
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In preparing this document, OEHHA is responding to state legislation enacted in 1992.  Senate 
Bill (SB) 1731 (Stats. 1992, Ch. 1162) requires OEHHA to develop risk assessment guidelines 
for implementing the “Hot Spots” Act.  Assembly Bill (AB) 2728 (Statutes of 1992, Chapter 
1161; California Health and Safety Code Section 39660) added a mandate to the Toxic Air 
Contaminants Program that all Federal Hazardous Air Pollutants be identified as Toxic Air 
Contaminants.  The Health and Safety Code also requires OEHHA to use a margin of safety when 
estimating levels of exposure that may cause adverse health effects.  This margin of safety must 
account for heterogeneity within human populations and uncertainty related to the applicability 
and completeness of the available data.  To help meet the requirements of AB 2728 and SB 1731, 
OEHHA described and evaluated methodology to estimate acute RELs and derived such levels 
for specific chemicals.  The acute RELs are designed for use in the Air Toxics “Hot Spots” 
Program. 
Figure 1. REL development process 
Prioritize chemicals to be evaluated
 
(select from list of substances in Appendix A)
 
D 
conduct literature search
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identify & evaluate existing standards � if appropriate, adopt as REL
 
D
 
appropriate standards do not exist
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choose best study, emphasizing human data 
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identify critical biological endpoint 
D 
estimate threshold for effect (NOAEL) 
D 
temporal/dosimetric adjustments (time extrapolation, HEC) 
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account for uncertainties in data
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D 
Reference Exposure Level (REL) 
(listed in Appendix B) 
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OEHHA and the Air Resources Board (ARB) have set up a procedure to facilitate the extensive 
public comment and peer review necessary for implementation of AB 2728 and SB 1731 (Figure 
2).  This process includes internal OEHHA and Cal/EPA review, consultation with the California 
Air Pollution Control Officers Association (CAPCOA), a public comment period, and public 
workshops.  In addition, this document has been reviewed by the Scientific Review Panel onToxic 
Air Contaminants administered by the ARB.  A draft of this document was released for public 
comment in January 1995.  We have responded to public comment and updated and revised the 
chemical-specific information. The State’s Scientific Review Panel on Toxic Air Contaminants 
reviewed this document and provided comments which were incorporated into this final draft. 
1.1.3  Implementation of Risk Assessment Advisory Committee (RAAC) Recommendations 
The California Environmental Protection Agency (Cal/EPA) Risk Assessment Advisory 
Committee (RAAC) was a panel of scientists convened under Chapter 418, Statutes of 1993, 
Health and Safety Code, Section 57004, to review the health risk assessment practices within 
Cal/EPA. The RAAC issued a report on its findings (Risk Assessment Advisory Committee, 
1996).  In the completion of the acute REL document, the RAAC recommendations were 
carefully considered (Table 1). 
Table 1.  Implementation of RAAC Recommendations 
RAAC 
Recommendation 
Implementation 
Formalized peer review 
program 
This document was reviewed by an advisory committee of non-governmental 
scientists: the Scientific Review Panel on Toxic Air Contaminants, prior to 
adoption. 
Input from risk  This document has been reviewed by risk assessors and managers of the Cal/EPA 
managers and from  Boards and Departments.  The document has also been reviewed by representatives 
external stakeholders  of the Air Quality Management and Air Pollution Control Districts, as part of the 
California Air Pollution Control Officers Association review.  The early draft of 
this document was distributed for comment to others, including external 
stakeholders.  Two public workshops were held, one in Northern California and 
one in Southern California to solicit stakeholder input.  Many changes were made 
in response to the input. 
Balance level of effort  The selection of chemicals for intensive review in this document was based in part 
with importance  on the importance of the chemical within California.  Emphasis was placed on 
developing health levels for those substances with high emissions or of concern to 
risk managers. The project incorporated all available risk assessment information 
from U.S.EPA, NAS, and other authoritative bodies. 
Coordinate effort with 
U.S.EPA 
The project made use of all available risk assessment information.  At the time of 
preparation of this document, no final U.S.EPA documents were available.  A draft 
U.S.EPA report for consideration of accidental exposures to 12 chemicals was 
released in 1997 (CFR 62 No. 210; Oct 30, 1997).  These were reviewed, but since 
they are subject to change, were not incorporated into the OEHHA document.  The 
draft was sent to U.S.EPA’s ORD for review and technical issues were discussed 
with U.S.EPA staff. 
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RAAC 
Recommendation 
Implementation 
Incorporate 
consideration of effect 
severity 
Concerns that severely adverse and high incidence effects should be addressed 
differently from mild and/or rarely encountered effects were addressed by 
incorporation of intermediate LOAEL uncertainty factors. In addition, the data are 
presented based on a classification scheme of severity.  Adverse effects were 
classified as mild, severe, and life-threatening.  Information was also provided, 
when available, on the effects that could result from doses above the REL. 
Additional research will be needed to use more sophisticated approaches to this 
problem. 
In general, the committee recommendations were well addressed.  Complete implementation of all 
committee recommendations will require additional efforts and research beyond the scope of the 
current project.  In particular, developing alternative approaches to some areas of uncertainty now 
addressed with default assumptions will require extensive data collection and analyses. 
1.2  List of Substances Considered 
All substances compiled by the ARB for the Air Toxics “Hot Spots” list of substances were 
considered for evaluation and inclusion in this guidance.  The substances included on the Air 
Toxics “Hot Spots” Program List are those substances found on lists developed by the 
International Agency for Research on Cancer (IARC), the U.S. Environmental Protection Agency 
(U.S.EPA), the U.S. National Toxicology Program, the ARB (list used in the Toxic Air 
Contaminant Program), the Hazard Evaluation System and Information Service (State of 
California), or on the Proposition 65 list of carcinogens and reproductive toxicants (State of 
California).  The complete list of substances whose emissions must be quantified is contained in 
Appendix B. 
Several exposure guidelines as well as published toxicological and epidemiologic literature serve 
as sources of information for chemicals for which acute RELs are being developed.  These are: 
California Ambient Air Quality Standards (CAAQS) developed by the State of California; 
Emergency Exposure Guidance Levels (EEGLs) and Short-term Public Emergency Guidance 
Levels (SPEGLs) developed by the NAS; Emergency Response Planning Guidelines (ERPGs) 
developed by the American Industrial Hygiene Association (AIHA); and Immediately Dangerous 
to Life and Health (IDLH) levels developed by the National Institute of Occupational Safety and 
Health (NIOSH). 
1.2.1  Priority For Evaluation Of Chemicals 
Substances were prioritized for the development of acute RELs on the basis of several criteria 
(Table 2).  All 32 chemicals for which acute noncancer RELs appeared in the Air Toxics “Hot 
Spots” Program Revised 1992 Risk Assessment Guidelines (California Air Pollution Control 
Officers Association, 1993) were considered for evaluation.  This was done to maintain 
consistency in the Hot Spots program and, by using existing information as much as possible, to 
conserve resources.  Additional substances were chosen from the ARB’s Air Toxics “Hot Spots” 
6
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emissions inventory based on: (1) the availability of California ambient air quality standards, (2) 
the magnitude of emissions in California, or (3) known toxic properties.  The list of 51 substances 
that have been evaluated with the methods delineated in this Technical Support Document is 
contained in Appendix A. 
Table 2.  Prioritization Process for Acute Toxicity Exposure Levels 
Listed in CAPCOA (1993) Document  California Ambient Air Quality Standard 
1.  Acrolein  (not already listed by CAPCOA) 
2.  Ammonia  1.  Carbon monoxide 
3.  Arsine 
4.  Benzyl chloride  High Emissions 
5.  Carbon tetrachloride  (High on ATEDS emissions inventory) 
6.  Chlorine  1.  Arsenic and compounds 
7.  Copper and compounds  2.  Benzene 
8.  1,4-Dioxane  3.  Chloroform 
9.  Ethylene glycol monobutyl ether  4.  Chloropicrin 
10. Ethylene glycol monoethyl ether acetate  5.  Copper and compounds 
11. Ethylene glycol ethyl ether  6.  Epichlorohydrin 
12. Ethylene glycol methyl ether  7.  Isopropyl alcohol 
13. Formaldehyde  8.  Methanol 
14. Hydrochloric acid  9.  Methyl bromide 
15. Hydrogen cyanide  10. Nitric acid 
16. Hydrogen fluoride  11. Phenol 
17. Hydrogen sulfide  12. Styrene 
18. Mercury (inorganic)  13. Sulfuric acid 
19. Methyl chloroform  14. Toluene 
20. Methylene chloride  15. Vanadium pentoxide 
21. Nickel and compounds  16. Vinyl chloride 
22. Nitrogen dioxide 
23. Ozone  Other known toxic compounds 
24. Perchloroethylene 
25. Phosgene  1.  Acrylic acid 
26. Propylene oxide  2.  Carbon disulfide (CEPRC list) 
27. Selenium and compounds  3.  Triethylamine 
28. Sodium hydroxide 
29. Sulfates 
30. Sulfur dioxide 
31.  Xylenes 
1.3  Time Frame of Interest 
In the Air Toxics Hot Spots program, routine industrial emissions are evaluated for potential 
public health impacts.  Chronic exposure is evaluated using ambient air concentrations of emitted 
chemicals averaged over a year.  The annualized average air concentration forms the basis for 
both chronic noncancer and cancer risk evaluation.  In reality, exposure over a 24-hour period 
does not occur at a continuous level.  Facility emissions may fluctuate considerably, with daily and 
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hourly maximum and minimum concentrations.  The commonly used air dispersion models 
account for only some of this variation as they can only accommodate emissions data entered as a 
single value in pounds emitted per hour or per year.  However, the models can calculate 
concentrations hour by hour throughout a year, giving an indication of the one-hour maximum 
exposure concentrations.  The hourly fluctuations are a reflection of the changing meteorological 
conditions that are included in the model. 
In general, the one-hour modeled maximum concentrations in the Air Toxics Hot Spots program 
are used in a hazard index approach in order to evaluate “acute” exposures and potential public 
health impacts from such exposure.  Modeled concentrations of several hours are used for some 
reproductive/developmental toxicants (see section 1.6.1). The hazard index is the ratio of the 
modeled concentration to the acute reference exposure level.  If the ratio exceeds one, then the 
risk manager needs to consider whether risk reduction is appropriate.  An exceedance of one does 
not mean adverse effects will occur.  Rather, it is an indication of the erosion of the margin of 
safety for exposure to that chemical. 
1.4  Criteria for Development of Acute Severity Levels 
Acute severity levels are concentration levels at or below which specified health effects are not 
expected to occur.  Toxicological responses to acute exposures follow a graded response, 
dependent on the exposure dose (determined by concentration and time).  Dividing this graded 
response into several categories facilitates the development of graded acute severity levels for 
each chemical, based on the severity of effect.  OEHHA has chosen to follow the NAS guidelines 
(NRC, 1993) to divide these responses into three severity levels, as detailed below. 
The Air Toxics Hot Spots Program uses the reference exposure levels, derived from the most 
sensitive endpoint of toxicity, for the risk assessment process.  Designation of the effects of 
exposure to increasing doses into severity categories will likely be helpful to risk assessors 
evaluating exceedances by helping them to better understand the practical implications of the 
endpoint of concern.  Furthermore, the proximity of the REL to the next severity level may help 
risk managers in making decisions on appropriate actions.  In a brief review of approximately 300 
risk assessments submitted by facilities complying with the Air Toxics Hot Spots Program, 
OEHHA found 20% of the facilities with exceedances of the acute reference exposure levels, 
ranging from 2-fold to as high as 500-fold. 
1.4.1  Definition of Acute Severity Levels 
This methods document is focused on the development of three categories of acute severity levels 
in accordance with criteria established by NRC (1993): the level protective against mild adverse 
effects, the level protective against severe adverse effects, and the level protective against life-
threatening effects (see Figure 3).  Each of these three acute exposure levels is determined for a 
one-hour exposure duration.  While NAS established these categories for the evaluation of 
accidental chemical releases, the toxicological principles validating the three severity levels are 
applicable to any acute exposures.  However, the major focus of this document is in developing 
acute RELs for the preparation of risk assessments for non-emergency routine releases.  Thus, the 
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RELs used in the risk assessment are generally levels protective against mild adverse effects; a 
few are based on severe effects (e.g., reproductive/developmental). 
A central assumption in the development of acute noncancer toxicity levels is that all toxicologic 
endpoints included under these levels are considered to have a threshold for adverse effects. 
However, the threshold may not be observable and, in some cases, may only be estimated.  Areas 
of uncertainty in estimating effects among a diverse human population are addressed using 
extrapolation and uncertainty factors (UFs). 
Protection against carcinogenicity and against the adverse health effects of chronic exposures are 
not considered in these guidelines.  For this reason, chemicals should be evaluated separately for 
their carcinogenicity and for any additional chronic health effects that may occur.  Methods for 
these evaluations are provided in the related OEHHA documents entitled Technical Support 
Document for Describing Available Cancer Potency Factors and Technical Support Document 
for the Determination of Noncancer Chronic Reference Exposure Levels. 
1.4.2  Hazard Index Approach 
RELs are used by the Air Toxics “Hot Spots” Program as indicators of the potential adverse 
health effects of chemicals.  A “hazard index” approach is used to estimate potential health effects 
resulting from hazardous substances by comparing measured exposure levels to calculated RELs. 
This approach assumes that multiple sub-threshold exposures to chemicals acting on the same 
target organ could result in an overall risk of developing an adverse health effect. 
For many facilities a large number of chemicals may be emitted or may be present in the air at the 
location of the receptor or exposed population.  To assess the cumulative impact of several 
chemicals present at the same time, it is important to consider the interaction of effects of the 
toxicants.  Unless specific information is available to the contrary, the interaction of two or more 
chemicals is assumed to be additive for a given toxicological endpoint.  This may underestimate 
the effect in the cases in which interactions are synergistic or overestimate it if the effects are not 
additive or are antagonistic. 
An underlying issue in chemical interactions and additivity is the concept of a threshold. 
Exposure to a single chemical in the air may not result in a toxic response if it is below the 
threshold necessary to elicit a response.  However, simultaneous exposure to two similar 
chemicals at sub-threshold levels may result in a toxic response.  This is taken into account by 
adding the individual ratios of modeled concentrations to acute RELs for chemicals that impact 
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Figure 3.  Acute Severity Exposure Levels for 1-hour Durations
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the same target organ or system (Appendix A lists RELs and toxicologic endpoints).  For a
 
particular target organ or system, the HI is calculated as follows:
 
HI = C1 / REL1 + C2 / REL2 + . . . + Ci  / RELi 
where for i substances with the same toxicological endpoint, 
HI = hazard index 
Ci  = 1-hour maximum concentration for the i
th substance 
RELi  = acute REL for the i
th substance 
Target organs or systems considered for hazard index calculations are general categories that may 
include varied effects (Table 3).  For example, the target system, “Respiratory System,” includes 
upper airway irritation as well as lower airway effects, such as bronchoconstriction.  This 
approach assumes additive interactions, as explained above.  Because the precise relative 
contributions of exposure to multiple substances that principally affect different areas of the same 
physiologic system (in the previous example, the respiratory system) are unknown, this approach 
may under- or over-estimate the effects of chemical interactions in certain cases.  However, in 
most cases this approach provides an appropriate health protective assumption.  We have 
indicated in Appendix A, Table A-1 which toxicological endpoints are relevant to the specific 
REL for each chemical.  While the REL is based on the most sensitive endpoint, some 
toxicological endpoints are manifested at exposures close to that which induces the toxicological 
endpoint that serves as the basis for the REL.  Therefore, some chemicals should be evaluated for 
impacts on multiple target organs or systems.  In addition, predisposing conditions are known to 
increase susceptibility to some chemicals.  The target organs for those predisposing conditions 
should also be included in the hazard index approach.  The target organs to be evaluated for 
hazard index are presented in Table A-2 in Appendix A, and in each chemical summary in 
Appendix C. 
Table 3. Target organs or systems used in acute hazard index calculations 
Hazard Index Targets  Health Effects Included Among the 51 RELs 
Hematologic System  Hemolysis; anemia; platelet abnormalities; effects on 
hematopoietic stem cells 
Cardiovascular System  Aggravation of angina 
Nervous System  Electroencephalograph (EEG) results; performance on 
neurobehavioral or neuropsychological tests; clinical 
neurological exam; headache, lightheadedness, dizziness 
Eyes  Irritation of eyes; histological changes to eye tissue 
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Alimentary Tract  Hepatotoxicity; nausea, vomiting 
Immune System  Lymphocyte proliferation; host resistance to infection 
Reproductive/Developmental  Fetotoxicity; teratogenicity; intrauterine growth 
retardation; preimplantation loss; altered behavior in 
offspring 
Respiratory System  Irritation of nose and throat; increased mucus 
production; histological changes in nasal epithelium; 
histologic changes in lung tissue; lung function following 
inhalation challenge (see Table 8) 
Skin  Irritation of skin 
Physiological Response to Odors  Headache; nausea 
1.4.3  Relationship of RELs to Severity Levels 
OEHHA has defined the lowest available acute severity level as the REL.  It is important to note 
that the level protective against the lowest severity level for a given chemical may be associated 
with a severe, rather than a mild, toxic effect for the following reason.  Adverse health effects that 
are minor and reversible are classified as mild effects (U.S.EPA effect severity level 5 or less, see 
Table 5).  However, the most sensitive detectable adverse effect of a chemical may be a severe 
effect (U.S.EPA effect severity level 5-9, see Table 5).  For chemicals with three severity levels, 
the level protective against mild adverse effects is considered the REL; for chemicals for which 
such a level is not appropriate (i.e., does not exist), the level protective against severe adverse 
effects is the REL.  For example, the most sensitive endpoint found in the literature for arsenic 
and related compounds was reproductive toxicity, a severe effect (Acute Toxicity Summary for 
Arsenic, Appendix C); thus, for arsenic, the REL is a level protective against severe adverse 
effects. 
For most compounds there are three identifiable severity levels.  However, as stated above, there 
are some chemicals for which all severity level criteria do not apply.  Those chemicals for which a 
severe toxicologic effect may occur below the level at which mild adverse effects occur will have 
fewer severity levels described.  For example, there would be no level protective against mild 
adverse effects for a chemical if reproductive toxicity, considered a severe adverse effect, was the 
most sensitive endpoint, as is the case for carbon disulfide.  Additionally, the toxicology data for 
some chemicals may be lacking and thereby not permit the establishment of a particular level.  The 
amount of data and the quality of the information will ultimately determine which acute exposure 
levels are identified.  As more data become available, either in the toxicologic literature or from 
guideline committees, such as U.S.EPA or the NAS, the acute exposure levels may be updated. 
12
 Determination of Acute Reference Exposure Levels for Airborne Toxicants 
March 1999 
1.5  Populations of Concern 
Acute RELs are intended to protect the individuals who live or work in the vicinity of emissions 
of these substances.  The general population consists of individuals with a wide range of 
susceptibility.  The susceptibility may be transitory or chronic.  Individuals in the general 
population who may be at greater risk for developing adverse effects following chemical exposure 
include those with increased exposure (e.g., children, adults engaged in physical activity), those 
undergoing physiological change (e.g., children, pregnant women and their fetuses), individuals 
with impaired physiological conditions (e.g., elderly persons, persons with existing diseases such 
as lung, heart or liver disease), and individuals with lower levels of protective biological 
mechanisms due to genetic variability within the population (U.S.EPA, 1994a).  Less susceptible 
individuals are healthy adults without any genetic or biological predisposition that may increase 
sensitivity to the chemical of concern. 
Acute RELs are intended to protect both individuals at low risk for chemical injury as well as 
identifiable sensitive subpopulations (highly susceptible or sensitive individuals) from adverse 
health effects in the event of exposure.  However, they may not protect hypersensitive individuals 
(those exhibiting idiosyncratic responses that cannot be predicted from studying the health effects 
of the substance). 
While OEHHA has attempted to identify specific sensitive subgroups for each substance from the 
literature, it has not been possible to identify all conditions predisposing toward adverse health 
effects following exposure to toxic substances.  Because RELs pertain to inhalation exposures, 
the lungs are often the major target organ of toxicity, and asthmatics are frequently identified as a 
sensitive group.  For most compounds, the range of intraindividual variability is poorly 
characterized.  An exception is sulfur dioxide, which has been extensively studied in both normal 
as well as asthmatic individuals.  In a study of asthmatic subjects, Horstman et al. (1986) found 
that there was a 7-fold distribution in the range of sulfur dioxide concentrations required to 
produce bronchoconstriction.  Thus, it is reasonable to conclude that asthmatics may be at least 
seven times as sensitive to the effects of sulfur dioxide as normal individuals. 
An analysis of human variability in threshold responses in pharmacodynamic and toxicologic 
studies by Hattis (1996) has shown that human variability in response can often be well modeled 
by a log-normal distribution and that the magnitude of the variability depends greatly on the 
endpoint and slope of the dose-response curve.  In their analysis, some human threshold responses 
ranged over more than 3 orders of magnitude.  Because the range of variability within the human 
population for most responses is unknown, there may be a proportion of the population for whom 
the acute RELs will not be protective.  It is OEHHA’s intent that, to the maximal extent possible, 
the levels will protect nearly all individuals.  As more susceptible groups are defined, it is our 
intent to adjust the levels as necessary to protect such individuals. 
1.6  Exposure Duration and Patterns 
As indicated in Section 1.3, the focus of acute RELs is generally a one-hour exposure.  While 
shorter and longer durations may also provide useful information, the one-hour increment is 
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consistent with hour-by-hour monitoring or modeling that is generally conducted for facilities 
under the Hot Spots program.  The exceptions in this document include RELs based on several 
hours exposure for reproductive/developmental endpoints (see Section 1.6.1). The acute REL 
may be adjustable to other exposure durations.  Sometimes it is necessary to extrapolate from 
other experimental exposure durations to a one-hour exposure duration.  This is described in 
Section 3.4. 
The distribution and concentration of a chemical following predictable continuous or intermittent 
emissions will be influenced by meteorological conditions and topography.  The most useful 
descriptors of exposure are the duration and the concentration to which people were exposed 
during the time period involved.  Several acute exposure guidelines, for example, EEGLs and 
ERPGs, are expressed in terms of a 1-hour duration.  In order to maintain a practical and standard 
time frame, a 1-hour exposure duration was chosen for the determination of the acute RELs. 
However, as mentioned previously, health effects of concern may occur hours to days after 
exposure ceases.  For example, the onset of pulmonary edema may be delayed for up to 24 hours 
following exposure to phosgene at doses several fold higher than the REL. 
1.6.1  Exposure Concentration Averaging Period 
The acute REL is a concentration that is not likely to cause adverse effects in a human population, 
including sensitive subgroups, exposed on an intermittent basis to that concentration for one hour 
(or in the case of reproductive/developmental endpoints several hours as indicated in individual 
toxicity summaries).  Intermittent exposure is difficult to define.  U.S.EPA views intermittent 
exposure as that lasting less than 24 hours and occurring no more frequently than monthly 
(U.S.EPA, 1994b).  This is in part based on an assumption that an acute exposure concentration is 
at least 10-fold higher than the monthly average, and the presumption that individual exposures 
are independent of one another.  U.S.EPA (1994b) points out that very few chemicals will have 
sufficient data to determine safe “periodicity” of an acute exposure.  Thus, U.S.EPA (1994b) has 
identified three issues to be addressed: length of acute exposure, periodicity of exposures, and the 
relationship between the acute exposure and the chronic background.  These will be discussed 
below. 
In acute toxicology experiments, the study design usually involves exposures of short duration to 
an otherwise unexposed animal.  However, real world “acute” exposures occur intermittently, 
rather than as rare events in a lifetime.  Thus, the typical ambient exposure scenario is not 
reflected in the standard acute toxicology experimental design.  The possibility of cumulative 
effects from intermittent ambient exposure cannot be addressed in acute REL development. 
Hence, acute environmental exposures are considered by U.S.EPA to occur no more frequently 
than monthly.  U.S.EPA  also recommends that longer interexposure periods be established for 
chemicals with long clearance times or with evidence of cumulative or sensitizing effects.
2 
2 In April 1998 U.S.EPA updated its planned approach to the Acute Reference Exposure 
(U.S.EPA, 1998, an external review draft).  U.S.EPA defines the Acute Reference Exposure 
(ARE) as “the exposure (concentration and duration), with an uncertainty spanning an order of 
magnitude, that is not likely to cause adverse effects in a human population, including sensitive 
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A related exposure issue is the fact that peak exposures are superimposed on lower long-term 
exposures to the same compound.  This is also not reflected in the standard acute toxicology 
design.  For some compounds this will result in an increased body burden relative to the typical 
toxicology experimental design and in a potential lowering of the acute exposure needed to 
produce an adverse effect.  U.S.EPA’s approach is to assume that the peak exposures are at least 
10 times the monthly average so that the acute exposure can be considered relatively independent 
of the longer-term chronic exposure to the same substance (U.S.EPA, 1994b). 
Despite the inability to mimic typical human exposures in the laboratory, it is imperative to 
examine whether short-term exposures to peak concentrations might result in adverse public 
health impacts.  OEHHA’s RELs are intended to be compared to the modeled one-hour maximum 
(or multi-hour as noted for specific reproductive/developmental toxicants) concentrations used in 
the hazard index approach to risk assessment (described earlier).  OEHHA recommends that these 
acute RELs be used to evaluate exposures that occur no more frequently than every two weeks in 
a given year.  The two-week interval was chosen because in most acute toxicology experiments 
two weeks is the duration of time an animal is observed for signs of adverse outcome following 
exposure (U.S.EPA, 1996). 
An assumption in making this recommendation is that the REL is protective of adverse health 
effects that are not cumulative; thus, the effects of each peak exposure are independent of 
previous or subsequent peak exposures that occur as often as every two weeks.  This 
recommendation is only valid for substances that do not bioaccumulate.  When bioaccumulation is 
known to occur and body burden is associated with an adverse effect, longer interexposure 
periods should be specified. 
The modeled one-hour peak concentrations are typically much greater than the maximum average 
annualized concentrations used for determining chronic exposure and risk.  Thus, it is assumed 
that acute exposures are independent of the long-term average exposure based on the modeled 
annualized maximum average concentration.  However, under certain meteorological conditions 
(poor mixing, persistent calm winds), it is conceivable that there are many hours in a day or within 
a few days where exposures are close to the peak one-hour in any given year.  Concentrations 
close to the maximum one-hour exposure may occur many times during the year including on 
consecutive days.  In addition, it is conceivable that exposure concentrations close to the 
maximum may occur in consecutive hours.  Currently, OEHHA does not ascertain how often 
exposures close to the one-hour maximum occur in a given day, week, month or year.  This 
contributes to the uncertainty in evaluating the adverse health effects of peak one-hour exposures. 
subgroups, exposed to that scenario on an intermittent basis.”  Three methods for deriving AREs 
are described in the draft report: a NOAEL/UF approach, a benchmark approach, and a 
categorical regression approach (see Appendix D of this report).  An example of the derivation of 
the Acute Reference Exposure (ARE) for one chemical is given for each approach.  The 
NOAEL/UF and benchmark approaches are similar to those described in this document. 
However, we define acute exposure as a 1 hour exposure. 
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In evaluating chemicals with reproductive/developmental toxicity, we found that the standard 
experimental paradigm of repeated exposure over several days did not lend itself easily to 
extrapolation to a one-hour Reference Exposure Level (REL).  Since reproductive/developmental 
endpoints are frequently manifested in a small window of time during gestation, the standard 
protocol is to expose pregnant animals for several hours per day over several days during 
gestation in order to increase the power of the study to detect an effect.  The Scientific Review 
Panel discussed this point during their February 10, 1999 meeting.  Issues that affect the 
extrapolation to one hour include not only when the sensitive gestational period is, but also 
toxicokinetic issues.  For example, the animals are exposed for 6 hours per day but unexposed the 
remaining 18 hours in that day.  A rapidly metabolized toxicant capable of inducing a reproductive 
or developmental toxic response may not build up in the animal’s system to the point where it 
would induce a response.  A slowly metabolized chemical would build up in the animal despite the 
intermittent exposure.  Whether or not a single one-hour exposure could produce a reproductive 
or developmental adverse outcome depends on the toxicokinetics governing the concentration of 
the chemical in maternal and fetal tissues, timing of exposure, mechanism of action, and other 
factors.  These issues are not easily taken into account in extrapolating to a one-hour Reference 
Exposure Level.  As such, after public review and review by the Scientific Review Panel, OEHHA 
chose to use a single day’s exposure from the key study (usually 4 to 7 hours) as the basis of the 
REL calculation, without time extrapolation to an equivalent one-hour concentration.  Thus, for 
those RELs addressing a reproductive/developmental endpoint in this document, the REL is for 
whatever exposure duration was chosen for a single day in the experimental protocol.  For 
example, for arsenic, the experimental paradigm involved exposing pregnant animals for 4 hours 
per day over several days of gestation.  Thus the REL for arsenic is for a 4 hour exposure rather 
than a one-hour exposure.  This will require those assessing risks to calculate a 4-hour maximum 
for arsenic rather than a one-hour maximum to use in the hazard index approach. 
1.7  Cumulative Effects of Multiple Chemical Exposures 
Concomitant exposures to more than one chemical may cause effects that are equal to, less than, 
or greater than predicted from the effects observed with exposures to the individual chemicals 
(Ikeda, 1988; Jonker et al., 1990).  Of the thousands of potential combinations of chemicals in 
common use, only a small fraction has been tested for the potential that combined exposures 
could have synergistic or antagonistic properties.  Effects of multiple chemical exposures on 
human health remain an area for future study.  As noted earlier, in risk assessment exposures to 
multiple chemicals that cause similar health effects are treated as additive in the hazard index 
approach. 
1.8  Pre-Existing Exposure Guidelines 
Acute exposure levels have been developed by several different organizations.  However, there 
are no inhalation exposure values that were derived using a consistent basis to protect the public 
from planned industrial emissions.  Values designed for protection of the general public exist, but 
they are intended to address accidental releases and use methodologies that we have not been able 
to reproduce.  Occupational exposure guidelines are available for hundreds of substances, but 
16
     
 
 
  
Determination of Acute Reference Exposure Levels for Airborne Toxicants 
March 1999 
have an inconsistent basis, often have not incorporated recently available data, and are not 
designed to protect sensitive subpopulations.  The existing exposure guidelines reviewed for 
OEHHA’s acute severity levels are described below. 
1.8.1  Description of Existing Guidelines 
1.8.1.1  The California Ambient Air Quality Standards (CAAQS), promulgated by the Air 
Resources Board based on recommendations from OEHHA, are specified concentrations and 
durations of air pollutants which reflect the relationship between the intensity and composition of 
air pollution to undesirable effects.  When a CAAQS existed for a criteria air pollutant, it was 
adopted as the acute REL.  If necessary, a one-hour value was derived using time extrapolation 
(described below). 
1.8.1.2  An Emergency Exposure Guidance Level (EEGL) is defined by the National Academy 
of Sciences (NRC, 1986) as the ceiling concentration of a substance in air that may be judged by 
the Department of Defense to be acceptable for the performance of specific tasks during rare 
emergency conditions lasting for periods of 1-24 hours.  “Emergency” connotes an unexpected 
situation with potential for loss of life.  EEGLs are designed to provide guidelines for military 
personnel operating under emergency conditions that are peculiar to military operations and for 
which regulatory agencies have not set standards.  The methods used to derive the EEGLs are not 
always explicitly stated and EEGLS were not derived with the intent to protect the general public. 
However, the levels derived for sulfuric acid and for xylenes were deemed acceptable for use as 
levels protective against serious adverse effects. 
1.8.1.3  Emergency Response Planning Guidelines (ERPGs) are defined by the American 
Industrial Hygiene Association (1991) as concentration ranges where adverse health effects could 
be observed.  Although ERPGs were evaluated, they were not routinely adopted as acute severity 
levels because the methods for their derivation were not consistent, the AIHA did not always 
consider all relevant data, and they have a specific emphasis on responding to accidental releases. 
Three ERPGs are available for each substance; the AIHA definitions are provided below: 
1.8.1.3.1  The ERPG-1 is the maximum airborne concentration below which nearly all individuals 
could be exposed for 1 hour without experiencing other than mild transient adverse health effects 
or perceiving a clearly defined, objectionable odor. 
1.8.1.3.2  The ERPG-2 is the maximum airborne concentration below which nearly all individuals 
could be exposed for 1 hour without experiencing or developing irreversible or other severe 
health effects which could impair an individual’s ability to take protective action. 
1.8.1.3.3  The ERPG-3 is the maximum airborne concentration below which nearly all individuals 
could be exposed for 1 hour without experiencing or developing life-threatening health effects. 
1.8.1.4  Immediately Dangerous to Life and Health (IDLH) values are defined by NIOSH 
(1994, 1995) as 30-minute concentrations from which a worker could escape without injury or 
irreversible health effects in the event of respiratory protection equipment failure and above which 
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only “highly reliable” respirators are required.  These levels were designed for healthy workers in 
an exposure situation that is likely to cause death or immediate or delayed permanent adverse 
health effects or prevent escape from such an environment. 
1.8.1.5  The Short-term Public Emergency Guidance Level (SPEGL) is defined by the 
National Academy of Sciences (NRC, 1986) as a suitable concentration for unpredicted, single, 
short-term, emergency exposure of the general public.  In contrast to the EEGL, the SPEGL 
takes into account the wide range of susceptibility of the general public, but it is not designed for 
repeated or multiple exposures. 
1.8.1.6  The Threshold Limit Value-Time Weighted Average (TLV-TWA) and Short-Term 
Exposure Limit (STEL) are developed by the American Conference of Governmental Industrial 
Hygienists (ACGIH, 1991); similar, NIOSH recommended exposure limits also exist (NIOSH, 
1994).  The TLV-TWA is defined as the time-weighted average concentration for a normal 8­
hour workday and a 40-hour workweek to which nearly all workers may be repeatedly exposed, 
day after day, without adverse effect.  The STEL is defined as a 15-minute TWA exposure which 
should not be exceeded at any time during the workday. 
Occupational exposure limits have been used to derive chemical exposure guidelines for the 
general public (U.S.EPA, 1994a; National Air Toxics Information Clearinghouse, 1991; Robinson 
and Paxman, 1992).  More than 600 ACGIH TLVs and NIOSH RELs are available.  These values 
have been attractive because of the large number of accessible values and the concept that they 
are intended to protect a human population from inhalation exposures.  However, these values 
lack a consistent basis for derivation, are not designed for or recommended for protection of the 
general public, and in many cases may not prevent adverse health effects among workers (Roach 
and Rappaport, 1990). 
1.8.1.7 U.S.EPA’s Acute Emergency Guidance Levels (AEGLs) are currently being 
developed.  Several draft AEGL values were recently released for public comment (62 CFR, No. 
210).  However, these values focus on emergency planning and response, not on routine 
emissions and exposure, which are the focus of this document. 
1.8.1.8  U.S.EPA’s Air Pollution Warning Levels (40 CFR, Subchapter C, Part 51, 
Appendix L) indicate poor air quality that may endanger the public’s health and suggest that 
additional control actions are necessary to reduce the level of the pollutant.  Air Pollution 
Warning Levels are available for the following criteria air pollutants: sulfur dioxide, particulates 
10 mm or less in diameter, carbon monoxide, ozone, and nitrogen dioxide. 
1.8.1.9  U.S.EPA’s Levels of Concern (U.S.EPA, 1987) are defined as the concentrations of 
substances in air above which there may be severe irreversible health effects or death as a result of 
a single exposure for a relatively short period of time.  For most compounds, the level of concern 
is derived from the existing guidelines listed above (IDLH, TLV, EEGL or ERPG). 
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1.8.2  Priority for Adopting Existing Guidelines 
Almost all acute RELs were developed de novo for these guidelines.  However, existing 
guidelines for acute exposure were first reviewed.  If they were found to be appropriate, they 
were adopted as the relevant acute toxicity exposure level using the following order of preference 
(also see Table 4).  For the six criteria air pollutants carbon monoxide, nitrogen dioxide, sulfates, 
ozone, hydrogen sulfide, and sulfur dioxide, the CAAQS for short-term (1-hour) exposure is 
considered equivalent to a mild adverse effect level and is used as the REL, or one-hour values 
were derived by extrapolation from the 24-hour standard. 
When calculating response severity for levels above the REL, an extensive review was conducted 
of the existing guidelines described above.  Existing guidelines were chosen as a basis for severity 
levels above the REL when they accurately and completely reflected the scientific literature, 
considered sensitive populations and included appropriate margins of safety for public health 
protection.  On the basis of these criteria, existing guidelines were chosen in the following order. 
For the small number of substances for which a SPEGL was available for acute noncancer 
endpoints, this was the existing value of choice for preventing severe or disabling effects.  If no 
SPEGL existed but an EEGL was available, this was the next existing level of choice.  ERPG-2s 
were chosen for the severe or disabling effect level only if no EEGL existed.  ERPG-3s were used 
as estimates of levels protective against potential lethal effects, if appropriate.  In the past, IDLHs 
were poorly documented and were not deemed to be health-protective (Alexeeff et al., 1989). 
Since they have been recently revised (NIOSH, 1995), they were considered for adoption for the 
“life-threatening effect level” based on the adequacy of their documentation and their health 
protectiveness. 
19
  
� �
� �
�
�
�
 
Determination of Acute Reference Exposure Levels for Airborne Toxicants 
March 1999 
Table 4 . Order of preference for adopting existing guidelines for acute severity exposure levels 
Acute severity level  Order of preference
1 
Level Protective Against 
Mild Adverse Effects 
2 
Criteria air pollutant  CAAQS appropriate  adopt value
 not appropriate  derive value 
Non criteria air pollutant  derive value 
Level Protective Against 
Severe Adverse Effects 
U.S.EPA Air Pollution Warning Level 
SPEGL 
EEGL 
ERPG-2 
TLV-TWA 
U.S.EPA Level of Concern 
Appropriate guidelines do not exist  derive value 
Level Protective Against 
Life-threatening Effects 
ERPG-3 
IDLH 
Appropriate guidelines do not exist  derive value if possible 
1 See Section 1.8.1 for definition of acronyms. 
2 This level would be protective of essentially all adverse effects. 
2.  Hazard Identification 
2.1  Nature of Adverse Effects 
The toxic effects of chemicals are of varying types and degrees of severity.  The most important 
effects following an acute (one hour) exposure to a substance released into the atmosphere are 
usually respiratory effects.  Toxic effects from airborne substances may be due to exposure via the 
skin, eyes, and upper and lower respiratory tract.  Systemic effects, such as hemolysis or central 
nervous system injury, may result from absorption of material though the lungs, and, to a lesser 
extent, through the skin.  For a toxic endpoint to be considered due to acute exposure, the effects 
do not have to be observed immediately.  Rather, the effects may be observed hours to days 
following the acute exposure.  For example, acute exposure to phosgene may result in pulmonary 
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edema several hours later.  In the case of benzene, death may result from leukopenia days 
following high-level acute exposure. 
Certain chemicals, after a single exposure, have the potential to produce delayed adverse effects. 
Often acute toxicity tests do not have a sufficient follow up period to allow thorough assessment 
of the potential for delayed health effects from single exposures.  With respect to two kinds of 
delayed effects, cancer and reproductive or developmental harm, there is more information 
available.  Carcinogens are considered in the Air Toxics Hot Spots Program Risk Assessment 
Guidelines Part II: Technical Support Document for Describing Available Cancer Potency 
Factors.  Reproductive and developmental toxicants are considered in this document  because 
substantial research effort has been devoted toward specifically identifying such delayed effects. 
Some substances exert their toxic effects through their metabolites.  For example, methylene 
chloride’s acute toxicity is mediated through its metabolite, carbon monoxide.  Whenever 
possible, information on toxic metabolites is provided in the toxicity summaries.  When detailed 
information is available on the relationship of dose of the parent chemical to level of metabolite 
and the metabolite level to degree of toxic response, this is taken into account in developing the 
acute severity levels.  However, RELs and other acute severity levels are always expressed in 
terms of the concentration of the parent compound, not the metabolite. 
2.2 Definition of Adverse Effect 
OEHHA has chosen to adopt U.S.EPA’s general definition of adverse effects as “any effects 
resulting in functional impairment and/or pathological lesions that may affect the performance of 
the whole organism, or that reduce an organism’s ability to respond to an additional challenge” 
(U.S.EPA, 1994a).  All effects reported for a substance were not necessarily considered adverse. 
For example, the perception of an odor, even if objectionable, was not considered an adverse 
health effect unless accompanied by other symptoms or signs, such as nausea and vomiting. 
OEHHA has chosen to follow the guidance provided by NAS (NRC, 1993) in developing the 
acute severity levels.  Thus, for each compound evaluated for its acute toxicity, multiple effect 
level thresholds were identified.  U.S.EPA’s effect severity levels (Table 5) provided some 
guidance in categorizing adverse effects. 
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Table 5. U.S.EPA Effect Severity Levels (U.S.EPA, 1994) and Corresponding OEHHA Levels 
U.S.EPA 
Severity Level 
Effect Category  Effect  OEHHA Effect 
Severity Level 
0  NOEL  No observed effects.  < Mild 
1  NOAEL  Enzyme induction or other biochemical change, 
consistent with possible mechanism of action,  with no 
pathologic changes and no change in organ weights. 
< Mild 
2  NOAEL  Enzyme induction and subcellular proliferation or 
other changes in organelles, consistent with possible 
mechanism of action, but no other apparent effects. 
< Mild 
3  NOAEL  Hyperplasia, hypertrophy, or atrophy, but without 
changes in organ weight. 
£ Mild 
4  NOAEL/ 
LOAEL 
Hyperplasia, hypertrophy, or atrophy, with changes in 
organ weight. 
Mild 
5  LOAEL  Reversible cellular changes including cloudy swelling, 
hydropic change, or fatty changes. 
Mild / Severe 
6  (LO)AEL  Degenerative or necrotic tissue changes with no 
apparent decrement in organ function. 
Severe 
7  (LO)AEL/ 
FEL 
Reversible slight changes in organ function.  Severe 
8  FEL  Pathological changes with definite organ dysfunction 
that are unlikely to be fully reversible. 
Severe 
9  FEL  Pronounced pathological change with severe organ 
dysfunction and long-term sequelae. 
Severe 
10  FEL  Life-shortening or death.  Life-threatening 
NOEL - no observed effect level; NOAEL - no observed adverse effect level; LOAEL - lowest 
observed adverse effect level; AEL - adverse effect level; FEL - frank effect level. 
In addition to the histochemical and pathological effects in Table 5, OEHHA’s system for 
categorizing clinical symptoms and signs into severity levels is presented in Table 6. 
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Table 6.  OEHHA Categorization of Adverse Health Effects into Severity Levels
1 
Acute Exposure 
Level 
Symptoms  Signs/Laboratory Findings 
Mild Adverse  Mild subjective complaints with few 
to no objective findings: 
Mild mucous membrane (eye, nose,
 throat) irritation 
Mild skin irritation 
Mild headache, dizziness, nausea 
Statistically  significant findings of 
pre-clinical significance: 
Mild conjunctivitis 
Mild lung function changes
2 
Abnormal immunotoxicity
 test results 
Mild decreases in
 hemoglobin concentration 
Severe Adverse  Potentially disabling effects that affect 
one’s judgment and ability to take 
protective actions; prolonged 
exposure may result in irreversible 
effects: 
Severe mucous membrane
 irritation 
Blurry vision 
Shortness of breath, wheezing 
Severe nausea 
Severe headache 
Incoordination 
Drowsiness 
Panic, confusion 
Clinically significant findings: 
Findings consistent with
 central or peripheral nervous
 system toxicity 
Loss of consciousness 
Hemolysis 
Asthma exacerbation 
“Mild” pulmonary edema 
Clinically significant lung
 function changes
2 
Cardiac ischemia 
Some cardiac arrhythmias
  e.g., atrial fibrillation 
Renal insufficiency 
Hepatitis 
Reproductive/developmental
 endpoints
 e.g., infertility, spontaneous
 abortion, congenital
 anomalies 
Life-threatening  Potentially lethal effects: 
Severe pulmonary edema 
Respiratory arrest 
Ventricular arrhythmias 
Cardiac arrest 
1 This table is intended to provide examples of health effects commonly considered for each level.  It is
 
not meant to be a comprehensive list of all possible health effects.  Please refer to the text of this
 
document and to the individual toxicology summaries for chemical-specific information.
 
2 Refer to Table 7 for detailed categorization of lung function tests.
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2.3  Identification of Adverse Effect 
Several factors need to be considered when identifying an appropriate adverse health endpoint for 
each compound.  These include weight of evidence, the strength, consistency, and specificity of 
the associated adverse health effect, the temporal association, and the coherence (scientific 
plausibility) of the health effect. 
2.3.1  Weight of Evidence 
Although a formal scheme has not been adopted, a descriptive analysis of the strengths and 
weaknesses of the studies used to derive acute RELs and other toxicity exposure levels is 
presented.  Issues such as observation of a dose-response relationship, reproducibility of findings, 
mechanism of action, and consistency with other studies were given weight in the OEHHA 
evaluation of acute RELs. 
2.3.2  Strength of Associated Adverse Health Effect 
The strength of an association between chemical exposure and adverse effect is assessed. 
Strength of association can be measured in terms of high observed effect incidence or high relative 
risk, statistical significance of differences between control and exposed groups, and a positive 
dose-response relationship.  For example, if an adverse effect noted in a low dose exposure group 
is not noted in a high dose exposure group, evidence for a causal association between the 
chemical exposure and the effect is greatly reduced. 
2.3.3  Consistency of Associated Adverse Health Effect 
Consistency of an association between chemical exposure and adverse effect is also evaluated. 
Relevant observations include similarity of effects noted in different studies and among different 
populations and/or species.  For example, if an effect was noted in only one of many studies of a 
particular strain of laboratory rodent, evidence for a causal association between the chemical 
exposure and the effect is weakened. 
2.3.4  Specificity of Associated Adverse Health Effect 
If an adverse health effect is specific to exposure to a substance, the case for causality is 
strengthened.  Arsine-induced hemolysis is an example of such a specific exposure-effect 
relationship.  Such highly specific associations are unusual, however, as chemical exposures 
generally cause multiple effects and chemical-induced health effects are generally comparable to 
similar health effects observed in the absence of exposure.  For example, eye, nose, and throat 
irritation, and headache may be observed following exposure to a wide variety of chemicals but 
may also be caused by other common stimuli (e.g., viral infection). 
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2.3.5 Temporal Association 
To strengthen the causal relationship, the adverse health effect should occur at a time following 
exposure that is consistent with the nature of the effect.  For example, respiratory irritation 
immediately following exposure to an irritant vapor such as chlorine gas is temporally consistent, 
whereas effects noted years later may not be.  On the other hand, tumors noted immediately 
following exposure might be temporally inconsistent with a causal relationship, while tumors 
arising after a latency period of months or years would be temporally consistent. 
2.3.6  Coherence of Adverse Health Effect 
Coherence or scientific plausibility of the association is also examined.  This is assessed in terms 
of evidence that the effects are consistent with the pharmacokinetics and mechanism of action of 
the chemical.  For example, reports of asthma and dermatitis caused by nickel are consistent with 
abnormal immunotoxicity tests following exposure to nickel compounds. 
2.4  Criteria for Studies Utilized to Identify Adverse Health Effects 
Although a wide variety of information may be reviewed, only key studies are used to develop 
acute severity levels.  The following criteria are used to determine the relevance and quality of 
data used for level development. 
Published, peer-reviewed data are preferred; exceptions include well-conducted industry-
sponsored studies that have been reviewed by other organizations but have not themselves been 
published in the literature, and doctoral dissertations.  For example, an industry study (IRDC, 
1985a) reviewed in a published article (Donald et al., 1991) was chosen as the basis for the severe 
adverse effect level for toluene.  A doctoral dissertation (Anglen, 1981) reviewed in a published 
article (Das and Blanc, 1992) was used as the basis for the chlorine REL (Appendix C).  Abstracts 
and review papers are not used for level development (the latter are considered secondary 
sources).  Studies involving a single chemical are given preference over those with multiple 
simultaneous exposures, especially if these are not quantified. 
Only studies that consider non-carcinogenic endpoints are considered for this document.  For a 
consideration of carcinogenic endpoints, please refer to the OEHHA document titled Technical 
Support Document for Describing Available Cancer Potency Factors.  Studies using multiple 
exposure doses and clearly indicating dose-response information are preferred (e.g., the Kulle et 
al. (1987) study used as the basis for the formaldehyde REL).  However, in some cases, an 
inadequate toxicology database may necessitate the use of older studies in which such information 
is unclear.  Usually such studies are chosen if they are the only existing acute inhalation studies 
and are consistent with the general toxicology database (e.g., the Dudley and Miller (1937) study 
used for the hydrogen selenide REL). 
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2.4.1  Selection of Key Studies 
An important step in the development of an acute REL is the identification of research studies that 
contribute most significantly to the weight of evidence as to the degree of hazard presented to 
humans by a particular substance (U.S.EPA, 1987; 1994a).  These studies may involve a human 
population studied in an epidemiological, clinical, or experimental exposure setting, or they may 
involve experimental studies with animals.  The key studies are given greatest weight in estimating 
a threshold for adverse effects and in identifying the nature of the critical adverse effect. 
2.4.1.1  Human Data 
Human data are logically most relevant to assessing human health effects associated with chemical 
exposures.  Much of the available human exposure data is via inhalation.  Principles for evaluating 
human exposure studies for use in determining health-based exposure levels have been discussed 
(NRC, 1986).  Whenever possible, RELs were developed based on human data; of the 51 acute 
RELs in this document, 36 are based on human health effects. 
Three types of human studies have been used in assessing health effects of chemicals: (1) 
epidemiological studies, (2) controlled exposure experiments, and (3) case reports.  Each of these 
three study types can provide important information needed to protect public health.  When using 
these studies for risk assessment, several factors are important in evaluating their quality and in 
determining the level of certainty associated with their use. 
2.4.1.1.1  Epidemiological Data 
Epidemiological studies generally produce data on effects of chemical exposure to a large number 
of persons. Areas of concern when interpreting epidemiological studies include exposure 
measurement, health effects measurement, and accounting for covariables and confounding 
variables (Lebowitz, 1983).  The population studied may consist of the general public or 
employees exposed at the workplace to varying concentrations of airborne chemicals. 
Exposure measures frequently represent the greatest weakness of available epidemiological 
studies.  Continuous, long-term exposure monitoring of individual subjects is rarely available. 
Frequently it is necessary to use limited, short-term, exposure monitoring data, which in many 
cases are not specific to the individuals under study, in order to derive an estimate of what the 
individual exposures may have been.  Occupational exposures may vary over time as industrial 
hygiene practices change and individuals change jobs.  The degree to which air concentrations can 
be adequately estimated is critical in determining the usefulness of an epidemiological study. 
Health effect measures in epidemiological studies also frequently differ from those reported in 
experimental animal studies and must be carefully examined.  Human health effect measurement 
generally consists of recording observable effects and conducting non-invasive tests.  Health 
effects data are compared with those compiled from a non-exposed group and may be presented 
as incidence, standardized mortality ratios, or relative risk ratios.  Health effects with a long 
latency may be missed if the study duration is inadequate. 
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Covariables and confounding variables should be controlled or removed from the study.  Co-
exposure to other chemicals is an important concern as a potentially confounding effect. 
Occupational studies raise an additional concern in that generally healthy workers may be less 
sensitive to the adverse effects of chemical exposures than others in the general population, 
including children, the elderly, and persons with preexisting medical conditions.  Bias may also be 
present where a workplace is disproportionate by gender (NRC, 1986).  While occupational 
studies provide important information, they are rarely used as key studies for acute toxicity 
exposure level development, as the duration of exposure is generally over a much longer period of 
time than is relevant for the acute reference exposure levels. 
Negative epidemiological studies present an additional difficulty in interpretation.  Estimating the 
power of the study to detect adverse effects can be useful in providing an indication of the 
maximum incidence consistent with the failure to show that the exposed group was statistically 
different from the control group.  Also, statistical confidence limits can be put around a negative 
finding, i.e. around the relative risk (RR) of 1. 
2.4.1.1.2  Controlled Human Exposure Studies 
Controlled exposure studies have the advantages of having quantified exposure concentrations 
and of being conducted with human subjects, thus combining two important features of human 
epidemiological and animal toxicity studies (Hackney and Linn, 1983).  The limitations of such 
studies are that they may (1) involve small sample sizes, (2) be of very short exposure duration, 
and (3) assess effects through subjective measurements that might miss significant health effects. 
In spite of these potential shortcomings, controlled studies in human subjects, especially in 
sensitive subpopulations such as asthmatics, are given preference over animal studies in the acute 
REL development process.  Human studies were used only if they were consistent with the 
standard ethical practices of investigation at the time they were conducted.  The preferred study is 
a modern, ethical study approved by an Institutional Review Board for Human Studies. 
2.4.1.1.3  Case Reports 
Individual case reports of adverse effects associated with exposures to a chemical can be useful, 
especially as qualitative confirmation that effects observed and quantified in animals also occur in 
exposed humans.  Multiple case histories with the same endpoint are especially relevant. 
However, these reports are generally not appropriate for quantitation because of the very small 
sample size and the unquantified exposures (Goldstein, 1983). 
2.4.1.2  Animal Data 
Many acute toxicity animal studies have been conducted, although studies that address the range 
of toxic effects (from mild to life-threatening) may not be available for many substances. 
Identification of the most appropriate animal species requires consideration of all available data 
relevant to prediction of human effects from animal observations.  Studies of the most sensitive 
species have frequently been selected as key studies.  Such an approach has the advantage of 
27
 Determination of Acute Reference Exposure Levels for Airborne Toxicants 
March 1999 
offering maximal protection, especially since humans may be more sensitive than laboratory 
animals in response to chemical exposure (Lehman and Fitzhugh, 1954).  However, the animal 
species most sensitive to a substance is not necessarily that most similar to humans in developing 
adverse effects from a particular exposure.  In general, of the animals used in laboratory studies, 
non-human primates are considered to be the most similar in response to exposures to toxic 
substances. 
Selection of the animal model and key study can be influenced by what is known about human 
health effects, and relevant areas of similarity and dissimilarity between humans and the animal 
species may be established (Calabrese, 1982).  Comparison of human and animal 
pharmacokinetics and metabolism may be useful in selecting the relevant animal model for 
predicting human health effects.  For example, hamsters and rabbits have much greater metabolic 
rates than monkeys (Plopper et al., 1983).  This may increase or decrease their susceptibility 
relative to humans.  However, in most instances it is not possible to determine which species 
responds most like humans. 
An experimental study should have a clear rationale and protocol, use Good Laboratory Practice 
Standards, and use appropriate analysis methods (CFR 1983 a, b).  Experimental study designs 
and criteria recommended by the NTP have been reviewed (Chhabra et al., 1990).  Appropriate 
statistical analysis of the results is important (Muller et al., 1984).  However, the goal of 
protecting public health must be weighed with experimental design so that important endpoints 
are not missed and that responses of relevant species are not ignored.  Furthermore, it is 
important that there not be disincentives to conducting good studies in order to avoid the 
establishment of reference exposure levels. 
3. Dose Response Assessment 
3.1  Severity of Adverse Effects 
Following acute exposure, health effects of varying severity may be observed and are determined 
by the extent of exposure, or the dose.  Although the relationship between exposure and health 
outcome is a continuous one, effects may be categorized into discrete severity levels.  Specific 
toxic effects that may be observed at each level are identified for each chemical.  The most easily 
specified health effect for which exposure indices can be developed is death.  Less severe effects, 
though less well defined, may also result in significant adverse health consequences. 
We have defined two additional graded categories of toxic effects.  Except for death, these graded 
effect levels are not sharply demarcated but each merges into adjacent categories.  Figure 3 
depicts how the dose-response relationship is a continuous phenomenon.  The dose is a factor of 
concentration and duration of exposure.  In general, as dose increases, so does the severity of the 
response.  Increased severity of physiologic response (from one acute severity level to the next) 
may involve the same receptor(s).  For example, for hydrochloric acid, the REL (level protective 
against mild adverse effects) is protective of eye and nose irritation.  At higher exposure 
concentrations, the severe adverse effect level is protective against severe eye, nose and throat 
irritation.  And at higher concentrations still, the life-threatening level protects against lower 
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respiratory effects, including pulmonary edema, which may lead to death (Acute Toxicity 
Summary for Hydrochloric Acid, Appendix C). 
Alternatively, for other compounds, increasing severity of response may involve different 
receptors or organ systems.  For example, the REL for methanol is based on subtle neurological 
impairment, a mild adverse effect, while the level protective against severe adverse effect is 
protective against developmental or reproductive toxicity (Acute Toxicity Summary for 
Methanol, Appendix C). 
It is important to note that exposure at or above the REL will not necessarily result in adverse 
health consequences.  Conversely, there may be individuals exhibiting idiosyncratic responses who 
may experience unpredictable health effects at shorter exposure durations or at concentrations 
below these levels.  For a list of several common reactions (symptoms) and observable findings 
(signs) that may be observed following exposure to hazardous substances and their categorization 
into the aforementioned levels, see Table 6.  It is not practical to include a comprehensive listing 
of all reactions and endpoints reported or considered for the 51 chemicals evaluated so far; 
therefore, only commonly considered endpoints are listed.  Please refer to individual chemical 
summaries (Appendix C) for a discussion of the reactions and toxicological endpoints reported for 
individual chemicals. 
3.2  Levels of Adverse Effect 
In developing acute exposure levels and RELs, we have applied the methods described in the 
NAS publication, Guidelines for Developing Community Emergency Exposure Levels (NRC, 
1993).  The three acute severity levels for one-hour exposure durations are defined below (also 
see Figure 3).  However, the risk management concerns of emergency planning and response are 
not incorporated into these definitions.  Instead, the levels are defined strictly based on 
toxicological and medical criteria.  Appendix A lists 51 chemicals for which acute RELs have 
been developed by OEHHA.  The toxicologic endpoints considered in deriving the RELs are also 
listed.  The acute toxicity summaries are included with these guidelines as Appendix C. 
3.2.1 Level Protective Against Mild Adverse Effects 
The level protective against mild adverse effects refers to the concentration of an airborne 
substance (a gas, vapor, aerosol or aerosolized particle) below which exposure for one hour is 
predicted to result in no adverse health effects in nearly all of the population.  Exposure to 
concentrations above this level may result in mild adverse health effects, such as enzyme induction 
or biochemical changes consistent with the mechanism of action, and reversible subcellular or 
cellular changes (U.S.EPA effect severity level 0-5, Table 5), mild irritation of the eyes, nose or 
throat or other minor physiologic changes of short duration, such as subtle neurologic changes 
detectable only by neuropsychological testing, not by clinical examination (e.g., REL for 
methanol). 
This level is intended to be protective of adverse health effects which are long-lasting (i.e., those 
that persist beyond the duration of exposure) and those which affect judgment or impair the ability 
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to respond.  For example, following exposure above the mild adverse effect level (but below the 
severe adverse effect level), an irritant gas might produce eye and nose irritation and an organic 
vapor may cause headaches; however, these effects are expected to resolve soon after exposure 
ceases. 
3.2.1.1  Lower Airway Responsiveness 
Lower airway effects are often the most sensitive physiologic response following inhalation 
exposure to certain chemicals.  Because these endpoints are frequently used for REL 
development, we have defined specific criteria for tests of lower airway function to be considered 
in categorizing effect severity.  In some individuals, the lower airways respond acutely to various 
stimuli by decreased airway diameter (Woolcock, 1994).  Although various methods are used to 
measure pulmonary function, airway responsiveness is commonly and easily assessed and is a 
sensitive indicator of airway narrowing in response to external agents (Gold, 1994; Woolcock, 
1994).  While varying spirometric criteria have been used for the determination of airway 
hyperresponsiveness (Bernstein et al., 1992; Cherniak et al., 1995; Eschenbacher et al., 1992; 
Jubber et al., 1993; Wiebicke et al., 1990), the standards used in this document are consistent 
with previously specified guidelines and research protocols (Aris et al., 1995; Eiser et al., 1983; 
Sterk et al., 1993). 
To be considered a mild effect, pulmonary function changes detected by spirometry must be the 
most sensitive adverse health effect observed for a particular chemical.  Following inhalation 
exposure to the chemical, the following spirometric changes (compared to pre-exposure findings) 
are criteria for inclusion as a mild effect: (1) statistically significant but clinically insignificant 
changes in forced expiratory volume in 1 second (FEV1) (i.e., <20% decrement in FEV1 
compared to pre-exposure baseline); or (2) statistically or clinically significant changes in specific 
airway resistance (SRaw) or airway conductance (SGaw) following inhalation challenge with the 
chemical of interest (clinical significance is a 100% increase in SRaw or a 50% decrease in SGaw) 
without a 20% drop in FEV1 or symptoms consistent with bronchoconstriction, such as chest 
tightness, wheezing and shortness of breath (Table 7). 
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Table 7. System for categorization of pulmonary function into effect severity levels. 
Endpoint
1  Mild  Severe  Life-threatening 
Spirometry Test 
Result (compared 
to baseline) 
Statistically significant 
but < 20% decrement in 
FEV1 
2 
> 20% decrement in FEV1  Not applicable 
Methacholine  > 100% increase in  100% increase in specific  Not applicable 
Challenge Test  specific airway  airway resistance (SRaw) 
Result  resistance (SRaw) or 
> 50% decrease in airway 
conductance (SGaw) 
no symptoms of 
bronchoconstriction 
< 20% decrement in 
FEV1 
or 
50% decrease in airway 
conductance (SGaw) 
accompanied by (1) 
symptoms of 
bronchoconstriction or 
(2) > 20% decrement in 
FEV1 
Clinical Findings  None anticipated  Chest tightness, shortness 
of breath, wheezing 
Wheeze detected by 
examination 
Hypoxia or decreased 
oxygen saturation 
Status asthmaticus 
Respiratory arrest 
1	  A finding under one endpoint category is sufficient to categorize a response into a 
particular severity level. 
2 	 Forced expiratory volume in one second. 
3.2.2 	Level Protective Against Severe Adverse Effects 
The hallmark of a severe adverse effect level outcome is a change in organ function and/or tissue 
damage that may be detectable by clinical examination (U.S.EPA effect severity levels 5-9, Table 
5).  For example, loss of balance, asthma exacerbation, hemolysis, cardiac ischemia and adverse 
outcomes of a pregnancy are all clinically significant findings.  With some exceptions (such as 
adverse outcome of a pregnancy), effects may be reversible, although prolonged exposure may 
result in irreversible effects. 
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Exposure to an airborne substance above the level protective against severe adverse effects for 
one hour may lead individuals to seek assistance.  Exposures above this level may be immediately 
disabling by adversely affecting one’s judgment and the ability to take appropriate health-
protective actions during or directly following the exposure.  In addition to protection against 
immediate health effects, this level is meant to be protective of certain long-term effects 
potentially resulting from exposure to hazardous substances, such as reproductive endpoints. 
This document does not address carcinogenic effects.  Exposure above this level may, but does 
not necessarily, result in prolonged or irreversible effects following cessation of exposure. 
Although exposure at or above the level protective against severe adverse effects is undesirable 
and may require protective action, it does not a priori indicate that injury or illness would occur. 
This level is designed to protect the natural diversity of individuals within the population.  With 
increasing exposure concentration or duration above the severe effect level, there is greater 
likelihood of serious or irreversible health effects occurring in a greater proportion of the 
population.  Examples of adverse health effects above this level include severe eye irritation, 
marked upper or lower respiratory tract irritation (including dyspnea or bronchospasm), 
disorientation, blurred vision, vomiting, hemoglobinuria, arrhythmias and adverse outcomes of an 
existing or subsequent pregnancy. 
Since the lower airway is often the most sensitive endpoint for severe adverse effects following 
inhalation exposure, criteria for pulmonary function testing considered under this level have been 
specified by OEHHA (Table 7).  Pulmonary function test results considered under this level are a 
20% or greater decrement in FEV1 compared to baseline, with or without symptoms of 
bronchoconstriction such as wheezing, chest tightness and shortness of breath.  Alternatively, a 
100% increase in SRaw or a 50% decrease in SGaw compared to baseline, accompanied by 
symptoms of bronchoconstriction, is also consistent with a severe adverse effect.  Another 
pulmonary function test result that is consistent with a severe adverse effect level endpoint is 
forced expiratory volume in 1 second to forced vital capacity ratio less than 70% (FEV1/FVC < 
70%), which suggests obstructive airway disease.  Other measures of the integrity of the lung, 
such as the diffusing capacity (DL), a measure of the efficiency of gas exchange across the air-
blood barrier, may be taken into consideration, but would not be the sole determinant of the acute 
severity exposure level. 
Examples of aid that may be required above this level include: physical assistance needed because 
severe eye irritation hampers escape; medical intervention to prevent the progression of adverse 
health effects such as those due to hemolysis; and sheltering in place because activities outdoors 
may result in greater exposure and adverse health effects, such as vomiting, than a protected 
indoor setting. 
As with all health effects, certain individuals may be more susceptible to adverse health 
consequences following exposure above the level protective against severe adverse effects.  These 
sensitive individuals may suffer health effects that may require assistance at a lower level of 
exposure than the general population.  For example, individuals with asthma, who are likely 
following exposure to sulfur dioxide to exhibit bronchoconstriction at a lower concentration than 
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the general population, may require greater protection from this substance than nonasthmatic 
persons.  Acute severity exposure levels are designed to be protective for the range of susceptible 
persons in the general population. 
3.2.3 Level Protective Against Life-threatening Effects 
Any exposure above this level for more than one hour is potentially lethal, especially to sensitive 
individuals; and, as exposure duration increases, death becomes a high probability for all exposed 
persons (U.S.EPA severity effect level 10, Table 5).  If death does not occur, the probability of 
severe, irreversible injury increases with increasing exposure duration or concentration.  Examples 
of adverse health effects considered under this level include severe acute pulmonary edema and 
respiratory or cardiac arrest.  Only exposures that are potentially life-threatening shortly after 
exposure (within minutes to days) are considered.  Exposures with the potential to cause medical 
conditions that result in death months to years following exposure are not considered.  For 
example, carcinogenic effects are not considered in this document.  Health consequences that are 
immediately severe and may lead to death months later, such as pulmonary edema, are taken into 
account in developing the level protective against severe adverse health effects. 
3.3  Estimation of Threshold or Low Response Concentrations 
Noncancer health effects assessment has been based on the concept that a threshold concentration 
or dose exists below which no adverse effects would occur.  While such thresholds are observed 
among individuals, the existence and magnitude of a population threshold below which no 
members of the population would experience adverse effects cannot be demonstrated.  The entire 
population of concern is not examined, rather a sample of the population from which inferences 
are drawn is studied.  Therefore, it is not possible to distinguish whether a concentration is truly 
below a population threshold level for an adverse effect or is rather a level associated with a 
relatively low incidence of adverse effects which cannot be distinguished from background rates in 
the population. 
Two major strategies were used for dose-response assessment methods to determine thresholds of 
responses.  These are the Benchmark Concentration (BC) approach and the No Observed 
Adverse Effect Level (NOAEL) approach.  A description of an alternative approach that has been 
proposed but not yet adopted by U.S.EPA, Categorical Regression Analysis, is provided in 
Appendix D.  As explained earlier, existing exposure guidelines were first reviewed, and if 
appropriate, adopted as RELs and other acute severity levels.  When appropriate standards did 
not exist (the majority of cases), the methodologies described here were used. 
Of the methods presented, the preferred one is the Benchmark Concentration approach.  A 
comprehensive evaluation of the literature specific to a toxicant and of the quantal dose-response 
data is required to estimate levels using the BC method.  Supporting toxicological data will not, 
however, always be sufficient to permit this level of quantification.  Furthermore, the methods are 
not generally applicable for chemicals with large data gaps. We were able to use the BC approach 
to develop 2 RELs and several levels protective against severe or life-threatening effects. 
Limitations in available data preclude development of more RELs using the BC approach. 
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3.3.1 Benchmark Concentration 
The importance of a dose-response relationship in the evaluation of effects of chemical exposure 
is well established. The NOAEL approach (explained below) does not explicitly incorporate this 
information.  This led to explorations of the concept that a concentration estimated to be 
associated with a predefined low risk could provide an alternative to the NOAEL (Crump, 1984; 
Dourson et al., 1985; Dourson, 1986; Gaylor, 1988; Gaylor, 1989; Hartung, 1987; Mantel and 
Bryan, 1961; Mantel et al., 1975;).  Crump (1984) proposed the term “benchmark dose” and 
extensively evaluated this concept.  In this document, the term benchmark concentration (BC) is 
used since inhalation toxicology data are described in terms of air concentrations. 
The BC method is a mathematical and statistical approach to calculate chemical exposure levels 
(Alexeeff et al., 1992, 1993; Crump, 1984; Lewis and Alexeeff, 1989).  In this document, the BC 
is defined as the 95% lower confidence limit of the concentration expected to produce responses 
in five of every 100 subjects exposed at this dose.  A log-normal concentration versus response 
relationship is used to identify the concentration expected to produce a 5% increase in toxic 
response (TC05) via a maximum likelihood estimate.  This is graphically depicted in Figure 4. 
3.3.1.1  Selection of Appropriate Benchmark Concentration Criteria 
Suggested response levels for the BC have ranged from one in one million (Mantel and Bryan, 
1961) to 10% (Dourson et al., 1985).  The 1 to 5% response range approximates the lower limit 
of adverse effect detection likely to occur in typical human epidemiological and laboratory animal 
studies (Gaylor, 1992).  In 1995, using developmental toxicity data, the U.S.EPA Benchmark 
Dose Workshop concluded that a 1% response rate was likely to be too low, while either 5% or 
10% response rates were adequate for the purposes of estimating a benchmark concentration 
(Barnes et al., 1995).  One reason for this conclusion was the large difference (29-fold) between 
observed NOAELs and the 1% benchmark using developmental toxicity data.  Subsequently, the 
U.S.EPA (IRIS, 1997) has used a 10% response rate for benchmark concentrations when deriving 
chronic inhalation reference concentrations (RfCs).  However, in the case of a steep dose-
response relationship, the selection of benchmark incidence is less influential on the final value. 
For acute exposure studies, 1 and 5% incidence benchmark concentrations differed, on average, 
by less than 2-fold from the respective NOAEL (Fowles and Alexeeff, 1996).  Therefore, 
OEHHA chose a 5% response rate for the BC. 
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Figure 4.	  Log-probit modeling of dose-response data.  A benchmark 
concentration (BC) was estimated for a 5% increase in 
response (MLE05).  
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It is important to select an appropriate mathematical model for the type of data used for 
benchmark concentration calculations.  The log-normal model is among the most widespread 
models used for toxicity testing and has traditionally been used extensively for determination of 
acute lethality and other dichotomous responses (Finney, 1971; Rees and Hattis, 1994). 
Furthermore, the log-normal distribution aspect of the model is biologically plausible and accounts 
for some degree of inter-individual variability (Rees and Hattis, 1994).  Hattis (1996) showed that 
the log-normal relationship effectively modeled data from 126 human studies.  The Weibull model 
is used by U.S.EPA when determining benchmark concentrations for the chronic inhalation RfCs 
(US EPA, 1997).  However, a comparison of the Weibull and Probit models by OEHHA for acute 
inhalation toxicity data indicated that the Probit model provided a better statistical fit to relatively 
steep dose-response slopes.  Furthermore, the uncertainty in the estimates using Probit, as 
measured by the distance between maximum likelihood estimates and the respective 95% 
confidence interval, was reduced (Fowles and Alexeeff, 1996).   For these reasons, the Probit 
model was chosen over the Weibull model for use in deriving acute BCs for this document.  The 
log-normal model is described as follows: 
P(d) = a0 + [(1 - a0)F(a1 + (a2 * log10d))] 
where P(d) is the probability of a response occurring at dose d, F is the cumulative distribution 
function of the standard normal distribution, and a0, a1, and a2 are background, intercept, and 
slope terms, respectively.  The model makes no assumption of a background response in the test 
population in absence of control data.  If controls were observed to exhibit a response, then that 
response was factored into the calculation. 
The 95 percent lower confidence limit on concentration (LCL) takes into account the variability 
of the test population and is dependent on the number of subjects in the study.  The 95% LCL 
was recommended by the Benchmark Dose Workshop for use in benchmark calculations (Barnes 
et al., 1995).  The advantages of the BC are that it reflects the shape of the dose-response curve 
and takes into account the number of subjects involved in the study.  In addition, it is not 
necessary to obtain a no-observed adverse-effect level in order to determine an exposure level and 
the BC does not require an additional uncertainty factor if the NOAEL is estimated from a 
lowest-observed adverse effect level (see section 3.3.2 below). 
In spite of its advantages, the experimentally derived BC value contains areas of uncertainty.  For 
example, the studies used to estimate the BC may have been performed with animals rather than 
humans.  Also, the experimental duration of exposure may differ from that which is of interest for 
the establishment of exposure levels.  Additionally, the dose of toxicant delivered to the target 
tissue may differ between species and among humans and may depend on the type of activity in 
which the individual is engaged.  In general, higher levels of activity result in increased respiratory 
rates and in increased doses of inhaled chemicals delivered to the lungs, and possibly systemically. 
Another area of uncertainty is that there can be a large degree of variability in the number of 
people who respond at any exposure dose.  For example, there may be over a 10-fold variability in 
the irritation threshold (the concentration of a substance at which irritation of the eyes, nose 
and/or throat is first detectable) for chlorine (Anglen, 1980).  The BC will likely need to be 
modified by UFs to account for these concerns. 
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The use of UFs to estimate chemical exposure levels from BCs is based on similar 
recommendations for calculating U.S.EPA’s “reference dose” or RfD (Barnes et al., 1995). 
Uncertainty factors are applied to the BC for the following areas of uncertainty (Table 8): 
(1) animal to human extrapolation: 3-fold. 
(2) human intraspecies variability: 10-fold when estimating an exposure level based on an 
animal study, or 3-fold when based on a human study performed in healthy adults.  This 
UF is reduced to 1 if using data that includes an assessment of sensitive human sub­
populations. This UF can also be 10 if data indicate a wide variability in response in the 
human population. 
Table 8.  Uncertainty Factors Used with Benchmark Concentrations 
Type of Study  Intraspecies Variability  Interspecies Uncertainty  Total 
Uncertainty 
Animal  10  3  30 
Human (average)  3 (10)  1  3 (10) 
Human (sensitive)  1  1  1 
The BC is considered by some investigators to account for interspecies as well as experimental 
variability (Barnes et al., 1995).  To acknowledge the greater degree of certainty in a BC for 
acute inhalation toxicity compared to the NOAEL approach, an UF of 3, instead of the 
conventional 10, is applied when estimating the acute chemical exposure level from animal data 
(Table 8). 
Acute Toxicity Exposure Level = BC/(UFs) 
where  1 < UF < 10 
The rationale for the above UFs is illustrated in Figures 5 and 6.  When using animal data, a BC 
has greater precision than a NOAEL at estimating a true threshold of response in the animal 
population.  This is because the estimate of the number of animals affected at a given 
concentration can be estimated with accuracy.  The result of using more precise methodology is a 
reduction in the total uncertainty involved in extrapolating to a threshold of response for sensitive 
individuals.  The precise magnitude of this reduction is, by definition, unknown.  It is clear that 
the increased precision in estimating an animal threshold does not reduce human variability in 
response.  Therefore, OEHHA proposes that the typical 10-fold UF for interspecies 
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Figure 5.  Estimation of a human threshold from animal data.  Hypothetical distributions 
of human and laboratory animal responses to increasing concentrations of a chemical are 
shown. 
LOAEL (Lowest observed adverse effect level):  An example of an experimental LOAEL is 
shown, in this case the experimental LOAEL represents approximately 25% incidence in the 
experimental animal population.  If no NOAEL is determined in the experiment, a NOAEL is 
estimated using an uncertainty factor of up to 10. 
NOAEL (No observed adverse effect level):  An example of an animal experimental NOAEL is 
shown. The NOAEL can be estimated from the LOAEL using an uncertainty factor of up to 10. 
Estimated NOAEL (humans):  A NOAEL for average humans is estimated from the animal data 
using an uncertainty factor of up to 10. 
BC (Benchmark concentration): An example of an experimental benchmark concentration is 
shown.  In this case, the BC represents less than 10% incidence in the animal population, and, 
when combined with an uncertainty factor of 3, provides an estimate for a NOAEL in average 
humans. A further uncertainty factor of up to 10 is needed to protect sensitive individuals. LOAEL UF 
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Figure 6.  Estimation of an REL that is at or below the threshold for sensitive individuals 
from healthy human experimental data. A hypothetical distribution of human responses 
to an increasing concentration of a chemical is shown. 
LOAEL (Lowest observed adverse effect level):  An example of an experimental LOAEL is 
shown.  In this case the experimental LOAEL represents a 25% incidence in the general 
population.  If no NOAEL is determined in the experiment, a NOAEL is estimated using an 
uncertainty factor of up to 10. 
NOAEL (No observed adverse effect level):  An example of an experimental NOAEL is shown.  
The NOAEL can be estimated from the LOAEL using an uncertainty factor of up to 10.  In the 
case shown, the NOAEL represents less than 10% incidence in the general population and, 
when combined with an uncertainty factor of up to 10, results in a reference exposure level that 
is protective of the vast majority of individuals. 
BC (Benchmark concentration): An example of an experimental benchmark concentration is 
shown.  In the case shown, the BC represents less than 10% incidence in the general population, 
and, when combined with an uncertainty factor of up to 3, results in a reference exposure level 
that is protective of the vast majority of individuals. Determination of Acute Reference Exposure Levels for Airborne Toxicants 
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differences be reduced to 3-fold (the rounded geometric mean of possible UFs between 1 and 10). 
While the geometric mean is 3.16, U.S.EPA uses a single intermediate UF of 3.00 rather than 
3.16, while two intermediate UFs accumulate to 10 (U.S.EPA, 1994a).  Thus, to maintain 
consistency with U.S.EPA practice, UFs of 3 would generally be used for intraindividual 
variability to reflect decreased residual uncertainty when using a BC.  However, there may be 
some circumstances where it is appropriate to use an uncertainty factor of 10 in this approach, for 
example, where evidence indicates a wide variability in response to a toxicant in the human 
population.  When a REL is derived by applying the BC to an animal study, the UF for human 
variability remains 10-fold.  However, in the case of a BC calculation from a study involving 
healthy human subjects, an UF of 3 is proposed since the total uncertainty in estimating a 
threshold for sensitive humans is reduced by using human, rather than animal, studies.  Finally, if a 
BC can be determined in a study of a sensitive population, no UFs need be applied (U.S.EPA, 
1994a; NRC, 1993). 
As with the NOAEL method, if the duration of the experiment differs from that for which one is 
developing the REL, time extrapolation is performed to determine an appropriate exposure 
concentration.  The principles used in time extrapolation in the example below will be described in 
detail in section 3.4.1. 
Example: 
Formaldehyde is used as an example to illustrate the use of the benchmark concentration 
to calculate an acute reference exposure level.  The most sensitive noncancer endpoint for 
formaldehyde toxicity is eye irritation.  Kulle and colleagues (1987) observed mild to 
moderate eye irritation in human subjects exposed to formaldehyde for 3 hours.  Using a 
log-probit analysis (Crump, 1983), OEHHA calculated a 3-hour BC05 of 0.44 ppm 
formaldehyde (see Figure 7).  The 3-hour BC05 was adjusted to a 1-hour exposure level 
using the formula C
n * T =K, where n=2.  (See Section 3.4.1 on Time Extrapolation for 
the rationale for the use of this equation.) These calculations are summarized below: 
180-minute acute exposure level = 0.44 ppm
 
C = 60-minute acute exposure level
 
C
2 * (60 min)= (0.44 ppm)
2 * (180 min)
 
C = 0.76 ppm
 
Figure 7 contains a graphic representation of the derivation of a BC for formaldehyde. 
3.3.2  Use of No-Observed-Adverse-Effect-Levels (NOAEL) 
A No-Observed-Adverse-Effect-Level (NOAEL) may be defined as an exposure level with no 
biologically or statistically significant increase in the frequency or severity of adverse effects 
among an exposed population relative to a control group.  The NOAEL must be tempered by 
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Figure 7.  This figure depicts the derivation of the benchmark 
concentration [BC(05)] for formaldehyde.  These data, taken from Kulle and 
colleagues (1987), are the result of 3-hour exposures to formaldehyde 
resulting in mild to moderate irritation.  The BC(05) is the 95% lower 
confidence limit (LCL) of the dose producing a 5% response rate. Determination of Acute Reference Exposure Levels for Airborne Toxicants 
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appropriate statistical interpretation.  A NOAEL is sometimes incorrectly viewed as an estimate 
of a threshold level for adverse effects.  However, a NOAEL could be associated with a 
substantial (1-20%) but undetected incidence of adverse effects among the exposed population, or 
alternatively it could be many-fold lower than a true population threshold (Gaylor, 1992; 
Leisenring and Ryan, 1992). This is so because only a subset of individuals from the population 
has been observed, and because the experiment may not have been designed to observe all adverse 
effects associated with the substance.  Therefore one may not safely conclude that the study 
concentration or dose is not associated with any adverse effects.  Experimental exposure levels 
are usually selected following a range-finding experiment. U.S.EPA (1994a) determined that a 
NOAEL not associated with any biological effect (a “no observed effect level” or NOEL) 
identified from a study with only one dose level is unsuitable for derivation of an RfC for chronic 
exposure; likewise, a NOEL is inadequate for determining acute severity levels.  Because there is 
a limited availability of multi-dose studies for the variety of chemicals considered, OEHHA 
considers a NOAEL without an associated LOAEL identified in the same study (termed a free­
standing NOAEL) to be acceptable for use in deriving an acute REL if there are no other suitable 
studies and as long as the overall health hazard information for that substance is consistent with 
the NOAEL study. 
3.3.2.1  Derivation of Acute Reference Exposure Levels Using NOAELs 
The NOAEL approach is based on the application of uncertainty factors (UFs) to the maximum 
dose level causing no observable adverse effects for that endpoint (California Department of 
Health Services, 1991): 
NOAEL / UF = acute reference exposure level. 
The NOAEL is an estimate of a threshold level for the absence of toxic effects in a study 
population and is determined directly from the observations reported in a specific scientific study. 
Prior to the determination of a NOAEL, the literature is examined to identify the relevant toxicity 
endpoints, such as lethality or respiratory tract irritation.  Toxic endpoints are evaluated and a 
dose-response relationship is determined.  Acute severity effect levels are then established: (1) the 
most sensitive adverse effect is used to define the NOAEL for the REL (usually a mild adverse 
effect); (2) severe adverse effects, such as chemical injury which would be irreversible without 
medical intervention and reproductive endpoints, are used to identify NOAELs for the level 
protective against severe adverse effects; and (3) lethality or potentially fatal effects are used to 
identify NOAELs for the level protective against life-threatening effects. 
3.3.3  Use of Lowest-Observed-Adverse-Effect-Levels (LOAEL) 
A Lowest-Observed-Adverse-Effect-Level (LOAEL) may be defined as the lowest exposure level 
with a biologically and/or statistically significant increase in the frequency or severity of adverse 
effects among an exposed population relative to a control group.  The highest exposure 
concentration which results in biologic effects that are not considered adverse may be termed the 
lowest observed effect level (LOEL); this is identical to the NOAEL (U.S.EPA, 1994a).  If a 
NOAEL is not identifiable from the literature, it is estimated from the lowest exposure 
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concentration reported to produce the adverse effect; this is the lowest observed adverse effect 
level (LOAEL).  An uncertainty factor is applied to the LOAEL to estimate the NOAEL: 
LOAEL/UF = NOAEL 
A one-to-ten-fold uncertainty factor has been proposed to account for the higher health risk 
potentially associated with a LOAEL compared with a NOAEL (U.S.EPA, 1994a).  In general, a 
factor of 10 has been used in most previous assessments by U.S.EPA and OEHHA.  An 
uncertainty factor is applied to calculate a threshold level (NOAEL) from the LOAEL. 
The relationship between LOAELs and NOAELs has been examined for chronic exposures.  The 
effectiveness of a ten-fold LOAEL-to-NOAEL uncertainty factor was confirmed for several 
inhalation exposure data sets (Gift et al., 1993).  Kadry and associates (1995) showed that among 
a small data set (4 chemicals) LOAEL to NOAEL ratios were less than 5.  However, where only a 
LOAEL has been observed, the magnitude of the difference between the observed concentration 
and the maximum concentration where adverse effects would not be detected is uncertain. 
OEHHA staff consider a10-fold UF for extrapolation from a LOAEL to a NOAEL to be 
protective when applied to all types of studies. 
The RAAC recommended that OEHHA delineate situations where uncertainty factors less than 10 
could be used in the REL development process.  Although the use of an uncertainty factor less 
than 10 (an intermediate uncertainty factor) may be appropriate under certain circumstances, 
application of UFs less than 10 to acute exposures by other organizations (e.g., AIHA’s ERPGs, 
see Section 1.8.1) appears to be subjective and guidance in specific criteria as to when it is 
appropriate is lacking.  As discussed elsewhere, use of the benchmark concentration approach can 
address this issue directly.  However, in most circumstances there is insufficient data for a 
benchmark concentration approach.  Consequently, OEHHA developed specific criteria for the 
use of an intermediate uncertainty factor.  Based on an analysis of LOAELs and NOAELs 
reported in various toxicological studies, we found that in certain circumstances (extrapolating 
from a LOAEL to a NOAEL for both mild (sensory) irritation and lethal effects), UFs less than 10 
are justified (Alexeeff et al., 1997).  OEHHA uses UFs less than 10 in the following cases: (1) for 
extrapolating from a LOAEL to a NOAEL for mild adverse effects; and (2) for potentially lethal 
effects (life-threatening level).  In the case of the mild adverse effect, an analysis by Alexeeff et 
al., (1997) (Appendix F) of LOAEL to NOAEL ratios for over 100 datasets indicated that the 
95
th percentile of that ratio is 6.2.  The distribution is skewed to the right.  For some chemicals, a 
UF of 10 may not be adequate.  OEHHA has chosen a UF of 6 to extrapolate from the LOAEL to 
the NOAEL based on the analysis.  OEHHA has followed precedence set by U.S.EPA (1994a) in 
the use of an intermediate uncertainty factor of 3 when using lethality data to determine a level 
protective against life-threatening effects.  It is suggested that further analysis of the LOAEL to 
NOAEL relationship be undertaken to better evaluate the use and magnitude of this adjustment 
factor.  Results of such a detailed analysis could be used to improve the exposure level setting 
procedure in the future. 
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Example:Thirty six healthy human volunteers reported eye irritation after being exposed 
to 0.06 ppm acrolein for 5 minutes (Darley et al., 1960).  Subjects wore carbon-filter respirators 
during exposure, so that only the eyes were exposed to the test mixture.  An uncertainty factor of 
6 was applied for estimation of a NOAEL from the 5-minute LOAEL of 0.06 ppm.  An additional 
uncertainty factor of 10 was applied to account for sensitive individuals, resulting in a total 
uncertainty factor of 60.  For a complete derivation of this REL for Acrolein see Appendix C. 
If there exist multiple, non-identical NOAELs and LOAELs for the same compounds, the study of 
the best quality reporting the highest value for a NOAEL (preferred) or the lowest value for the 
LOAEL is used for the development of acute severity levels.  Preferably, a study should report a 
NOAEL as well as a LOAEL.  However, this is not always done.  As stated above, a free­
standing NOAEL (i.e., a NOAEL reported at the highest exposure concentration studied, with no 
reported LOAEL) is used as the basis for an acute toxicity exposure level only when there are no 
other appropriate studies on which to base the level and the dose-response data are consistent 
with other dose response information reported in the scientific literature. 
3.3.4  Accounting for Uncertainties in the Database 
Acute RELs and other toxicity exposure levels must address uncertainties in the available data. 
These areas of uncertainty are accounted for with the use of extrapolation factors or uncertainty 
factors.  Uncertainty factors are used extensively with human or animal toxicity data to estimate 
“safe” or “acceptable” exposure levels for humans (Dourson and Stara, 1983). Uncertainty factors 
are used by OEHHA in deriving acute RELs to account for the following, discussed below : 
1)potentially greater susceptibility to the toxic effects of exposure to substances in humans
 
compared with laboratory animals (Dourson and Stara, 1983; Vettorazzi, 1976);
 
2)the uncertainty involved in extrapolating from LOAELs to NOAELs (Gift et al., 1993;
 
Dourson and Stara, 1983); 

3)the large range of individual variability in the human population, e.g., low risk vs. high risk 
individuals (Vettorazzi, 1976; Hattis, 1996). 
4)other deficiencies in the study design (Bigwood, 1973; Dourson and Stara, 1983; Lehman and 
Fitzhugh, 1954; NRC, 1993); 
The use of uncertainty factors for determining “safe” or “acceptable” levels has been discussed 
extensively in the toxicologic literature (Alexeeff et al., 1994; Bigwood, 1973; CDHS, 1991; 
Dourson and Stara, 1983; NAS, 1977; U.S.EPA, 1989; Vettorazzi, 1976).  While most of the 
applications have focused on long-term exposure, many of the factors are applicable to acute 
inhalation exposure and are based on acute experiments.  Uncertainty factors used for each 
chemical are presented in Table 9. 
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Table 9. Uncertainty factors used in derivation of acute RELs 
Chemical  Interspecies  Sensitive 
Individuals 
LOAEL to 
NOAEL
2 
Methodology 
Used
3 
Total UF 
Acrolein  N/A  10  6  NOAEL  60 
Acrylic acid  10  10  N/A  NOAEL  100 
Ammonia  N/A  3  N/A  BC  3 
Arsenic  10  10  10  NOAEL  1000 
Arsine  10  10  N/A  NOAEL  100 
Benzene  10  10  N/A  NOAEL  100 
Benzyl chloride  10  10  6  NOAEL  600 
Carbon disulfide  10  10  N/A  NOAEL  100 
Carbon monoxide
1  N/A  1  1  NOAEL  1 
Carbon 
tetrachloride 
10  10  10  NOAEL  1000 
Chlorine  N/A  10  N/A  NOAEL  10 
Chloroform  10  10  N/A  NOAEL  100 
Chloropicrin  10  10  N/A  NOAEL  100 
Copper  N/A  10  N/A  NOAEL  10 
Dioxane  N/A  10  6  NOAEL  60 
Epichlorohydrin  N/A  10  6  NOAEL  60 
Ethylene glycol 
monobutyl ether 
N/A  10  N/A  NOAEL  10 
Ethylene glycol 
monoethyl ether 
10  10  N/A  NOAEL  100 
Ethylene glycol 
monoethyl ether 
acetate 
10  10  10  NOAEL  1000 
Ethylene glycol 
monomethyl ether 
10  10  10  NOAEL  1000 
Formaldehyde  N/A  10  N/A  BC  10 
Hydrochloric acid  N/A  1  N/A  NOAEL  1 
Hydrogen cyanide  10  10  N/A  NOAEL  100 
Hydrogen fluoride  N/A  10  N/A  NOAEL  10 
Hydrogen selenide  10  10  6  NOAEL  600 
Hydrogen sulfide  N/A  1  1  NOAEL  1 
Isopropyl alcohol  N/A  10  N/A  NOAEL  10 
Mercury  10  10  10  NOAEL  1000 
Methanol  N/A  10  N/A  NOAEL  10 
Methyl bromide  10  10  N/A  NOAEL  100 
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Chemical  Interspecies  Sensitive 
Individuals 
LOAEL to 
NOAEL
2 
Methodology 
Used
3 
Total UF 
Methyl 
chloroform 
N/A  10  N/A  NOAEL  10 
Methyl ethyl 
ketone 
N/A  10  6  NOAEL  60 
Methylene 
chloride 
N/A  10  N/A  NOAEL  10 
Nickel  N/A  1  6  NOAEL  6 
Nitric acid  N/A  1  N/A  NOAEL  1 
Nitrogen dioxide
1  N/A  1  N/A  NOAEL  1 
Ozone
1  N/A  1  1.3  LOAEL  1.3 
Perchloroethylene  N/A  10  6  NOAEL  60 
Phenol  N/A  10  N/A  NOAEL  10 
Phosgene  10  10  N/A  NOAEL  100 
Propylene oxide  10  10  6  NOAEL  600 
Sodium hydroxide  N/A  10  6  NOAEL  60 
Styrene  N/A  10  N/A  NOAEL  10 
Sulfates
1  N/A  1  N/A  NOAEL  1 
Sulfur dioxide
1  N/A  1  1  NOAEL  1 
Sulfuric 
acid/oleum 
N/A  1  N/A  NOAEL  1 
Toluene  N/A  10  N/A  NOAEL  10 
Triethylamine  N/A  10  N/A  NOAEL  10 
Vanadium  N/A  10  N/A  NOAEL  10 
Vinyl chloride  N/A  10  N/A  NOAEL  10 
Xylenes  N/A  10  N/A  NOAEL  10 
1	  The California Ambient Air Quality Standard was used as the basis for the acute REL; 
uncertainty factors may differ from those described in this document since different 
methodology was used for the derivation. 
2 	 N/A = Not applicable; when used in “Interspecies” column, indicates that human study was 
used as basis for REL; when used in “LOAEL to NOAEL” column, indicates that NOAEL 
was reported in study. 
3	  NOAEL = No observed adverse effect level methodology; BC = Benchmark concentration 
methodology. 
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3.3.4.1  Differences Between Human and Animal Susceptibility 
Although it is preferable to use human studies, risk assessment of chemicals must often rely on 
observation of experimental animals.  Of the many thousands of chemicals in existence, most have 
not been studied in human populations, and where human studies exist, there is often poor 
knowledge of exposure.  Furthermore, confounding factors may render cause and effect 
conclusions difficult.  A great wealth of scientific information shows that species differ markedly 
in anatomic, physiologic, and metabolic characteristics, and can vary greatly in terms of 
susceptibility to adverse effects from exposure to chemicals.  However, the differences between 
animal and human responses to toxic substances have not been delineated for all compounds of 
interest. 
To account for this area of uncertainty, a default factor of 10 is generally incorporated for 
extrapolation from animals to humans based on an assumption that an average human is likely to 
be at most 10-fold more susceptible to the effects of the substance than experimental animals. 
This is truly an “uncertainty” factor since we are unsure how humans would respond in contrast to 
the animals tested (Figure 5).  However, the uncertainty factor is based on the potential for 
greater sensitivity of humans and the larger surface area of humans, suggesting a 2- to 100-fold 
uncertainty factor (Krasovskii, 1976; Lewis and Alexeeff, 1989; Rall, 1969; Watanabe et al., 
1992; Weil, 1972; Willhite et al., 1986). 
The use of  uncertainty factor methodology is in contrast to practice in cancer risk assessment, 
where an allometric surface area correction and a 95% upper confidence limit of the slope of the 
dose response is used.  The UF approach is identical to that used by U.S.EPA (1994a) and 
recommended by NAS for drinking water standards.  Limited support for the concept of a 10-fold 
uncertainty factor was provided by Dourson and Stara (1983).  Khodair and associates (1995) 
showed that among a small data set (6 chemicals) animal NOAEL to human NOAEL ratios were 
less than 4.  Clearly, additional work in this area is warranted.  Recently, Schmidt et al. (1997) 
evaluated interspecies variation between human and five other animal species.  Sixty compounds 
had human data that could be matched to one or more animal species.  The animal to human 
Maximum Tolerated Dose (MTD) ratio of 10 represented approximately the 85
th percentile.  In 
other words, an UF of 10 to account for interspecies variability would be protective for 85% of 
chemicals.  Thus, use of this factor alone would not likely be protective of most individuals. 
However, this adjustment is not made without consideration of an intraspecies variability factor as 
well.  An analysis by Stickney et al. (1997) indicated that the use of the 10-fold interspecies and 
10-fold intraspecies uncertainty factors together would be protective of the 99
th percentile of the 
population. The use of interspecies uncertainty factors and the degree of protection afforded by 
those uncertainty factors for different endpoints (e.g., lethality, irritation) warrants further 
research. 
In Figure 1, we indicate that a dosimetric adjustment, such as the Human Equivalent 
Concentration (HEC) adjustment used by U.S.EPA might be appropriate in some circumstances. 
We did not conduct any HEC adjustments in developing the RELs for chemicals presented in 
Appendix C.  However, we may in the future use dosimetric adjustment to partially account for 
differences in animals and humans with respect to dose at a specified concentration. 
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3.3.4.2  Increased Susceptibility of Sensitive Individuals 
Acute RELs are intended to protect identifiable sensitive individuals from harm due to chemical 
exposure.  However, RELs may not necessarily protect individuals who may develop an 
idiosyncratic response which cannot be predicted from scientific investigation of the chemical. 
Susceptibility to harm from chemical exposure may vary among individuals due to genetic 
variability within the population, resulting in lower levels of protective biological mechanisms or 
increased metabolic activation (Hattis, 1996; U.S.EPA, 1994a; Eichelbaum et al., 1992; 
Grandjean, 1992).  Additionally, susceptibility to chemical-related health effects may vary over 
time for the same individual due to changing factors such as age, health status, and activity level. 
Thus, sensitive individuals may include children, pregnant women and their fetuses, elderly 
persons, those with existing diseases such as lung, heart or liver disease, and persons engaging in 
physical activity (U.S.EPA, 1994a).  Other factors, such as acute illness, may cause short-term 
variations in individual susceptibility.  Seasonal changes in absorption and toxicity have also been 
noted in laboratory animals (Barton and Huster, 1987). 
Healthy workers, the subject of most epidemiological studies, are often found to have lower rates 
of morbidity and mortality than the general population (Monson, 1986; Wen et al., 1983).  In 
studies of experimental animals, highly homogeneous, healthy strains are generally used.  Such 
strains may have much less variability in response than a more heterogeneous human population. 
Chizhikov (1973) found that animals in poor health were more likely to experience adverse effects 
from chronic oral exposure to chemicals than were healthy animals. 
A 10-fold uncertainty factor is used to account for variability within the human population.  But, 
in this case, the factor is not actually accounting for something unknown; instead it is accounting 
for the variability in the general population which we know exists but do not have enough data to 
quantify (Figure 6).  This factor accounts for the greater susceptibility to chemical toxicity of 
various sensitive subpopulations, including infants and children. 
A high degree of interindividual variability (2-to-30-fold) in response to chemical exposure has 
been reported (Krasovskii, 1976; Weil, 1972).  Hattis (1996) has shown that human variability in 
response to some medications may range over more than 3 orders of magnitude (>1,000-fold). 
Similar interindividual variability has been shown in airway responsiveness and lung volume 
among normal and asthmatic subjects (Bylin et al., 1995; O’Connor et al., 1987).  In a study of 
asthmatic subjects, Horstman et al. (1986) found that there was a 7-fold distribution in the range 
of sulfur dioxide concentrations required to produce bronchoconstriction.  Thus, it is reasonable 
to conclude that asthmatics may be at least seven times as sensitive to the effects of sulfur dioxide 
as normal individuals.  The interindividual variability has been recently modeled, indicating a 
distribution that ranges from 1 to >20 with a value of 10 for the 85
th percentile (Gillis et al., 
1997).  Thus, based on this analysis, the use of a 10-fold uncertainty factor would not be 
protective of approximately 15% of the population.  Further research into the considerations, 
circumstances, subpopulations, and endpoints of greater susceptibility is needed. 
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For acute RELs derived from NOAELs or LOAELs in healthy adults, OEHHA has applied a 10­
fold uncertainty factor to address the greater susceptibility of sensitive individuals.  In accordance 
with U.S.EPA guidelines (U.S.EPA, 1994a), when an exposure level is estimated from a study 
that includes the assessment of a sensitive human sub-population, an intraspecies factor of 1 is 
used.  Since the true degree of variability of response in the human population is unknown, the 
effectiveness of this method in providing protection to nearly all individuals is uncertain.  A 
summary of uncertainty factors used for acute REL development is given in Tables 9 and 10. 
Table 10. Uncertainty factors used in the derivation of acute RELs 
Methodology, study type  Nature of uncertainty  Uncertainty Factor 
Benchmark concentration, 
animal study 
Interspecies 
Intraspecies 
3 
10 
Benchmark concentration, 
human study 
Interspecies 
Intraspecies--study includes 
sensitive subjects 
Intraspecies--study does not 
include sensitive subjects 
1 
1 
3 or 10 
NOAEL, animal study  Interspecies 
Intraspecies 
3 or 10 
10 
NOAEL, human study  Interspecies 
Intraspecies--study includes 
sensitive subjects 
Intraspecies--study does not 
include sensitive subjects 
1 
1 
10 
NOAEL, any study  LOAEL--mild effects 
LOAEL--other than mild 
effects 
6 
10 
As noted by Dourson and Stara (1983), the steepness of the dose-response relationship affects the 
adequacy of the uncertainty factor for sensitive individuals. They summarized the range of dose 
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response slopes reported by Weil (1972), indicating that, based on studies of acute lethality, a 10­
fold factor was health-protective in most cases.  However, in our experience, dose response 
curves for acute lethality exposures are generally steeper than those for non-lethal exposures 
(Table 11). 
Table 11.  Comparison of slopes of mild and lethal effects
a. 
Chemical  Mild Effects
b  Lethality
c 
Acrolein 
(irritation) 
3.3  14.4 
Ammonia 
(irritation) 
6.9  14.3 
Vinyl chloride 
(CNS effects) 
7.5  31.9 
a	  Log-normal dose-response slope values are the mean of up to 5 studies. 
b	  Human data for mild effects include: Hine et al., 1961; MacEwen et  al., 1970; IBT, 1973; 
Verberk et al., 1977; Lester et al., 1963. 
Animal LC50 studies include: U.S.EPA 1992a; U.S.EPA 1992b; Philippin  et al., 1970; 
Champeix and Catilina 1967; Silver and McGrath 1948;  Appelman et al., 1982; 
Kapeghian et al., 1982; Prodan et al., 1975. 
Because the true variability is unknown, there may be a portion of the population for whom the 
acute RELs will not be protective.  It is OEHHA’s intent that, to the maximal extent possible, the 
levels will protect the general population including those in the high end of susceptibility.  As 
information defining susceptible individuals becomes available, it is our intent to adjust the 
methodology as necessary to protect such individuals. 
3.4  Effects of Exposure Duration 
Studies of adverse health effects associated with exposures in humans or experimental animals are 
generally conducted for time periods different from that which is of interest in the acute exposure 
scenario.  Typical exposure scenarios involve several hours for human exposures and several daily 
exposures for two weeks in animals.  OEHHA acute RELs, on the other hand, are 
designed to be protective for one-hour exposures (with the exception of some 
reproductive/developmental toxicants where the REL is for several hour exposures). 
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Acute inhalation toxicology studies (exposure duration of 8 hours or less) are preferred over other 
exposure routes.  In their absence, studies using exposures of longer durations may be employed 
if appropriate (e.g., symptoms noted after short period of time; reproductive/developmental 
endpoints).  If inhalation toxicity data are unavailable, studies on other exposure routes may be 
used.  Studies that include an adequate follow-up period (hours to days, depending on the 
chemical and endpoint) to account for delayed health effects are preferred to those that terminate 
observation immediately following exposure.  In order to adjust experimental exposure durations 
to one-hour, OEHHA uses a method termed “time extrapolation.” 
3.4.1  Time Extrapolation 
“Haber’s Law” states that the product of the concentration (C) and time of exposure (T) required 
to produce a specific physiologic effect is equal to a constant level or severity of response (K), or 
C * T = K (Rinehart and Hatch, 1964).  When the duration of experimental exposure differs from 
the desired exposure duration for which an acute exposure level is being calculated (in this case 1 
hour), a modification of Haber’s Law is used to adjust the experimental exposure duration to the 
desired duration of the acute exposure level: 
Cn * T = K, 
where n is a chemical-specific parameter greater than zero (ten Berge, 1986). When n is equal to 
1 (n=1), the toxicity of a chemical is equally dependent on changes in concentration and duration 
of exposure; when n is less than 1 (n<1), the duration of exposure is a greater determinant of 
toxicity than the concentration; finally, when n is greater than 1 (n>1), the toxicity of a chemical is 
determined to a greater extent by exposure concentration than by duration.  Ideally, the 
magnitude of n should be determined for all chemicals by evaluating the concentration versus 
response relationships for several different exposure durations.  However, this information is 
available for only a limited number of substances.  Empirically derived values of the exponent n 
range from 0.8-3.5 (ten Berge, 1986).  The time-concentration-response relationship depends on 
the time-frame considered and the endpoint measured.  There are usually multiple “n” values for a 
single chemical that are applicable to different response endpoints.  For example, the “n” for 
irritation of ammonia is 4.6, while the “n” for lethality of ammonia is 2. 
A risk assessment document published by the NAS (NRC, 1987) includes a general statement that 
Haber’s Law does not apply for “some irritants”.  However, no specific references are cited by 
NAS in support of this statement.  It is likely that the basis of this statement is the observation 
that for some substances, irritation appears to be solely concentration dependent.  However, the 
modified Haber’s Law presented here is able to accommodate any such empirical observations. 
For example, in those cases for which data exist to allow the determination of a concentration-
time relationship for irritants (e.g. chlorine, ammonia), an analysis by OEHHA revealed that both 
concentration and time of exposure contributed to the overall severity of effect, as described by 
Cn * T = K.  As concentration becomes the more important factor, the value of “n” will increase. 
Values of “n” greater than 3 suggest a strong predominance of concentration over time. 
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A modified Haber’s Law was applied to all of the chemical data sets analyzed in this document. 
This is consistent with a role for both concentration and time in the determination of the 
magnitude of irritation and other acute effects. 
Examples of time extrapolation using different empirically derived values of “n” are given as 
follows. 
Example: 
(a)For illustrative purposes, an example of time extrapolation for carbon tetrachloride is used. 
The empirically derived value for “n” in this case is 2.8 (ten Berge, 1986).  A NOAEL for 
lethality in rats of 7,300 ppm for 1.5 hours was reported by Adams et al. (1952).  A 1-hour 
level protective against life-threatening effects is estimated as follows: 
C
2.8 (1 hr) = 7,300
2.8 (1.5 hr), 
where C represents the desired 1-hour concentration in ppm.  Solving this equation for C 
yields a value of 8,440 ppm. 
(b)The example of ammonia is given to further illustrate time extrapolation.  The empirically 
derived value for the exponent “n” for ammonia is 4.6 (refer to Acute Toxicology Summary 
for Ammonia, Appendix C for further information on its derivation).  A hypothetical 6-hour 
exposure study in a sensitive human population reported that the no adverse effect level for 
severe mucous membrane irritation was 48 mg/m
3 ammonia.  The equivalent 1-hour 
concentration for this effect is calculated as follows: 
C
4.6 (1 hr) = 48
4.6 (6 hr), 
where C represents the 1-hour concentration for the effect described above.  Solving for C 
yields a 1-hour concentration of 71 mg/m
3. 
The value for the exponent “n” used by OEHHA in the acute toxicity summaries was chosen as 
follows.  First, when an empirically derived value for the exponent was available from the open 
literature, this was adopted for time extrapolation, using the modification of Haber’s Law as 
described above.  The values from the American Institute of Chemical Engineers (AICE, 1989) 
are included in Table 12, but were not used in the Technical Support Document since AICE 
(1989) does not give references for the sources of data.  When a derived value was not available 
and there were insufficient data from which to determine a value de novo, a default value for “n” 
was used.  As seen in Table 12, the published or OEHHA derived values for “n” range from 0.8 to 
4.6.  The mean value in this range rounds to 2, while the interquartile range (25%-75%), where 
most of the “n” values are found, is from 1 to 2.2. 
As noted in Section 1.6.1, the time extrapolation to one hour in the case of repeated dose studies 
for reproductive/developmental endpoints was not considered appropriate by the Scientific 
Review Panel.  OEHHA chose a single day’s exposure for each chemical (ranged from 1 to 8 
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hours) as the exposure duration for which the REL is to be applied. Thus, no time extrapolation is 
used for reproductive-developmental toxicants. 
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Table 12.  Value of the exponent n for various gases and vapors 
Chemical  n  Species/Effect  References, Comments 
Acrolein  1.2  rat/lethality (local 
irritant)* 
US EPA (1992a,b), derived by OEHHA 
Acrylonitrile  1.1  rat/lethality (systemic)  Dudley & Neal (1942); Appel et al. (1981), derived 
by ten Berge et al. (1986) 
Allyl chloride  0.5  rat/lethality (local irritant)  Adams et al. (1940), derived by OEHHA 
Ammonia  4.6  human/irritation  Rosenbaum et al. (1993) 
2.0 
2 
rat/lethality (local irritant)  Appelman et al. (1982) 
Arsine  2.2  rat/lethality (systemic)  IRDC (1985b), derived by OEHHA for 0.5 to 1 hr 
(n dependent on exposure duration) 
1.0  rat/lethality (systemic)  IRDC (1985), derived by OEHHA for 4 hr to 1 hr 
(n dependent on exposure duration) 
2  mice/lethality (systemic)  Levvy (1947) 
Benzene  2  not given  AICE (1989) 
Bromine  2.2  mice/lethality (local 
irritant) 
Bitron & Aharonson (1978), derived by ten Berge et 
al. (1986) 
Carbon monoxide  1  not given  AICE (1989) 
Carbon 
tetrachloride 
2.8  rat/lethality (systemic)  Adams et al. (1952), derived by ten Berge et al. 
(1986) 
Chlorine  2.8  rat/lethality (local irritant)  Zwart & Woutersen (1988), derived by OEHHA for 
0.5 hr to 1 hr (n dependent on exposure duration) 
1.0  rat/lethality (local irritant)  Zwart & Woutersen (1988), derived by OEHHA for 
4 hr to 1 hr (n dependent on exposure duration) 
1.3  mouse/lethality (local 
irritant) 
Zwart & Woutersen (1988), derived by OEHHA 
3.5  mouse/lethality (local 
irritant) 
Bitron & Aharonson (1978), derived by ten Berge et 
al. (1986) 
Chlorine 
pentafluoride 
2  rat, mouse, dog, 
monkey/lethality (local 
irritant) 
Darmer et al. (1972), derived by ten Berge et al. 
(1986) 
Crotonaldehyde  1.2  rat/lethality (local irritant)  Rinehart (1967), derived by ten Berge et al. (1986) 
Dibutylhexamethyle 
ne-diamine 
1  rat/lethality (local irritant)  Kennedy & Chen (1984), derived by ten Berge et al. 
(1986) 
1,2-dichloroethylene  2  (not applicable)/lethality 
(systemic) 
US EPA (1996), based on the mid-point range of n 
values from lethality data of ten Berge et al. (1986) 
Dimethyldichloro­
silane 
2  (not applicable)/lethality 
(local irritant) 
US EPA (1996), based on the mid-point range of n 
values from lethality data of ten Berge et al. (1986) 
Ethylene dibromide  1.2  rat/lethality (systemic)  Rowe et al. (1952), derived by ten Berge et al. 
(1986) 
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Table 12.  Value of the exponent n for various gases and vapors (cont.) 
Chemical  n  Species/Effect  References, Comments 
Ethylene imine  1.1  rat, guinea pig/lethality 
(local irritant) 
Carpenter et al. (1948), derived by ten Berge et 
al. (1986) 
Fluorine  1.9  rat/lethality (local irritant)  US EPA (1996), derived from LC50 data of 
Keplinger & Suissa (1968) 
1.8  mouse/lethality (local 
irritant) 
US EPA (1996), derived from LC50 data of 
Keplinger & Suissa (1968) 
1.6  guinea pig/lethality (local 
irritant) 
US EPA (1996), derived from LC50 data of 
Keplinger & Suissa (1968) 
Formaldehyde  2  not given  AICE (1989) 
Hydrazine  2  (not applicable)/lethality 
(systemic) 
US EPA (1996), based on the mid-point range of 
n values from lethality data of ten Berge et al. 
(1986) 
Hydrogen chloride  1  rat, mouse/lethality (local 
irritant) 
Darmer et al. (1972), derived by ten Berge et al. 
(1986) 
1.5  rat/lethality (local irritant)  Hartzell et al. (1985), derived by OEHHA 
Hydrogen cyanide  2.7  numerous species/lethality 
(systemic) 
Barcroft (1931), derived by ten Berge et al. 
(1986) 
Hydrogen fluoride  2  rabbits, guinea 
pigs/lethality (local 
irritant) 
Machle (1934), derived by ten Berge et al. (1986) 
Hydrogen fluoride 
(low humidity) 
1  rat/lethality (local irritant)  Haskell Lab. (1988), derived by OEHHA 
Hydrogen sulfide  2.2  cat, rabbit/lethality 
(systemic/local irritant) 
Lehmann (1892), derived by ten Berge et al. 
(1986) 
8.2  lethality (systemic/local 
irritant) 
Arts et al. (1989) 
Methyl bromide  4.0  severe morbidity 
(systemic/local irritant) 
Pharmaco LSR, Inc. (1994) derived by OEHHA, 
DPR 1996 
1  not given  AICE (1989) 
Methylenechloro­
bromide 
1.6  rat/lethality (systemic)  Torkelson et al. (1960), derived by ten Berge et 
al. (1986) 
Methylhydrazine  1.0  squirrel monkey/lethality 
(systemic and local 
irritant) 
Haun et al. (1970), derived by OEHHA 
1.0  dog/lethality (systemic and 
local irritant) 
Haun et al. (1970), derived by OEHHA 
Methyl isocyanate  1.1  human/eye irritation  Mellon Inst. (1963), derived by OEHHA 
0.5  rat/lethality (local irritant)  Kimmerle & Eben (1964), derived by OEHHA 
0.7  rat/lethality (local irritant)  Dow Chem. (1990), derived by OEHHA 
Methyl mercaptan  2  (Not applicable)/lethality 
(systemic and local 
irritant) 
US EPA (1996), based on the mid-point range of 
n values from lethality data of ten Berge et al. 
(1986) 
Methyl t-butyl ether  2.0  lethality (systemic)  Snam Progretti (1980), derived by ten Berge et al. 
(1986) 
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Table 12.  Value of the exponent n for various gases and vapors (cont.) 
Chemical  n  Species/Effect  References, Comments 
Nitrogen dioxide  3.5  guinea pig, mouse, dog, 
rat, rabbit/lethality (local 
irritant) 
Hine et al. (1970), derived by ten Berge et al. 
(1986) 
Nitric acid  3.5  not applicable (local 
irritant) 
US EPA (1996), based on NO2 from Hine et al. 
(1970) 
Perfluoroisobutylen 
e 
1.2  rat/lethality (local irritant)  Smith et al. (1982), derived by ten Berge et al. 
(1986) 
Phosgene  1  lethality (local irritant)  Rinehart & Hatch (1964) 
Propylene oxide  2.2  rat/lethality (local irritant)  Rowe et al. (1956), derived by OEHHA 
1.5  guinea pig/lethality (local 
irritant) 
Rowe et al. (1956), derived by OEHHA 
Sulfur dioxide  1  not given  AICE (1989) 
Tetrachloroethylene  2.0  rat/lethality (systemic)  Rowe et al. (1952), derived by ten Berge et al. 
(1986) 
Toluene  2.5  not given  AICE (1989) 
Trichloroethylene  0.8  rat/lethality (systemic)  Adams et al. (1951), derived by ten Berge et al. 
(1986) 
* Parentheses denotes whether the chemical acts locally or systemically to produce the effect. 
When extrapolating from an exposure duration that is greater than 1-hour to a 1-hour level, the 
value of n=2 was used by OEHHA.  The value of n=2 was chosen because it represents a whole 
number near the midpoint of the range of values, as described above.  When extrapolating from an 
experimental exposure duration of less than 1 hour to a 1-hour level, the value of n=1 was used. 
Using a value of n=1 is more health-protective than a value of n=2.  A value of n=1 results in a 
relatively rapid decrease in the derived REL when extrapolations are made from shorter to longer 
exposures.  For example, when extrapolating from a 10 minute exposure to a 60 minute exposure 
for chloropicrin, using n=1 results in an extrapolated NOAEL of 132 ppb; when using n=2, the 
extrapolated NOAEL is 320 ppb.  The default values for “n” bracket the interquartile range of 
possible values, and they are applied using health protective assumptions (Table 13). 
Table 13.  Exponents used by OEHHA for extrapolation to 1-hour acute RELs
1. 
Exponent (n) 
From less than 1 hour  1 
From greater than 1 hour  2 
1 Exponent, n, used in the formula C
n T = K 
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4.0 	Supporting Data 
The summaries describing the development of the REL for each chemical are found in Appendix 
C.  In addition, a list of abbreviations is provided in Appendix E.  All acute toxicity exposure level 
estimates (including those for RELs) will include a discussion of the information upon which the 
calculations are based.  This discussion includes the following key elements. 
1.	  Physical and chemical properties:  Descriptions include information on volatility, reactivity, 
stability, toxic secondary compounds, flammability, density, water solubility, color, taste, 
odor, and some additional properties. 
2.	  Occurrence and use:  The typical uses of the chemical are described as well as where it is 
likely to be found. 
3.	  Routes of exposure:  The routes of exposure that may lead to toxic effects are mentioned for 
each substance.  Since the intent of this document is to provide information on airborne 
toxicants, the data presented focuses on inhalation exposure studies and may be supplemented 
by relevant non-inhalation toxicology studies.  If inhalation data are unavailable or are of poor 
quality for a particular chemical, other routes of exposure may be considered for the 
development of acute severity levels.  For extrapolation from oral to inhalation exposures, 
methodology presented by U.S.EPA (1994a) should be used (see the Acute Toxicity 
Summary for carbon tetrachloride, Appendix C, as an example). 
4.	  Summary of toxic effects:  Toxic effects are described for relevant endpoints.  Where possible, 
all of the following attributes are mentioned: endpoint, test species, concentration or dose, 
duration and frequency of exposure, type of effect level (such as NOAEL), reversibility of 
findings, uncertainty factors applied, and acute severity levels calculated.  Endpoints of 
toxicity testing include, but are not restricted to, lethality, upper and lower respiratory effects, 
including mucous membrane irritation, and systemic effects.  Results from studies on a 
chemical’s mutagenicity, reproductive and developmental toxicity and immunotoxicity are also 
mentioned, where appropriate. 
5.	  Pharmacokinetics and metabolism:  A brief discussion of pharmacokinetics is included if 
information is available.  This may include significant routes of absorption, distribution, 
metabolism, and excretion.  The inhalation route of exposure is examined preferentially. 
Metabolites of the parent compound are identified. 
6.	  Other planning levels:  Inhalation exposure levels from other sources, such as TLVs, EEGLs, 
SPEGLs, and IDLHs are examined.  It is important to compare acute severity levels 
developed by OEHHA with existing values as a quality assurance measure and also to 
determine whether the use of other existing guidelines might lead air pollution control officers 
and planners into predicting that exposures are safe at potentially toxic concentrations.  The 
most scientifically valid and health-protective level is generally recommended by OEHHA; 
however, a discussion of the strengths and weaknesses of each existing level is not included in 
the toxicity summaries. 
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7.	  Quality assurance measures:  Weak or conflicting data are reviewed.  Studies are evaluated for 
any recognized violations of sound laboratory or statistical practices.  Any study with 
significant flaws is not used to justify RELs or acute exposure levels. 
8.	  Sources of data:  In the absence of well-documented experimental dose-response studies in 
humans, reliance on toxicological data from animal studies and human data from workplace 
and other accidental exposures is appropriate.  In addition, in vitro toxicity studies are 
consulted. 
9.	  References:  If a complete literature database search is available for a chemical but only a few 
were used for the acute toxicology summaries, only the latter are cited in the document; 
however, the complete reference list will be made available on request.  OEHHA has 
completed literature searches for all of the chemicals for which acute RELs were developed in 
this document. 
5.0 Areas for Further Research 
•	  There are a number of chemicals lacking adequate data on acute toxicity.  While we were able 
to develop RELs for the 51 compounds in this document, we could not develop levels 
protective against severe adverse effects or life-threatening effects in a number of instances 
due to the limitations of the database.  The following chemicals fall into that category: 
acrolein; acrylic acid; inorganic arsenic compounds; benzyl chloride; chloroform; chloropicrin; 
copper compounds; dioxane; epichlorohydrin; ethylene glycol monobutyl ether; ethylene 
glycol monoethyl ether acetate; hydrogen sulfide; isopropyl alcohol; inorganic mercury 
compounds; methanol; methyl chloroform; methylene chloride; inorganic nickel compounds; 
nitric acid, ozone; perchloroethylene; phenol phosgene; propylene oxide; selenium 
compounds; sodium hydroxide; sulfates, sulfur dioxide; sulfuric acid; toluene; triethylamine; 
vanadium pentoxide; xylenes.  Research is needed to adequately characterize the full-spectrum 
of effects following acute exposure of these substances. 
•	  There are about 450 chemicals on the Air Toxics Hot Spots list of substances to be quantified 
(Appendix B).  This is the list of substances which facilities must report in their emissions 
inventories.  We have to date only evaluated information on 52 of these compounds and 
developed acute RELs for 51 of these compounds.  While not all of the 450 chemicals have 
reported emissions in California, more work needs to be done in analyzing available literature 
for the remaining compounds. 
•	  The application of uncertainty factors to account for extrapolation from a LOAEL to a 
NOAEL warrants further analysis.  When evaluating dose-response relationships, the slope of 
the dose-response curve determines the distance between the LOAEL and the NOAEL from a 
particular study.  Some endpoints tend to have steep dose-response slopes and may not 
warrant a 10-fold uncertainty factor to extrapolate from a LOAEL to a NOAEL; other 
endpoints have a shallow dose-response slope and may warrant a 10-fold (or higher) 
uncertainty factor for extrapolating from the LOAEL to the NOAEL.  In this document, we 
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have used an intermediate uncertainty factor of 6 to extrapolate from the LOAEL to a 
NOAEL for mild irritation and a factor of 3 for that extrapolation for lethality.  This is based 
on an analysis of the distribution of the LOAEL to NOAEL ratios for 112 datasets.  If further 
analysis suggests revisions of the UF, it will be revised in future acute REL updates.  With 
further analysis, we may also be able to adjust the uncertainty factor for this extrapolation for 
other toxicological endpoints. 
•	  A related issue is the application of subchronic or repeated exposure studies to evaluating 
acute toxicity.  We have not used subchronic exposures routinely to evaluate acute toxicity 
RELs.  In addition, there are issues such as cumulative tissue injury that may be seen with 
repeated exposures that impact the quantitative analysis of acute toxicity.  Further research 
into these areas is warranted. 
•	  An interspecies factor of 10 is commonly used to extrapolate from animal studies to the 
human response.  In some cases, there may be reason that a smaller uncertainty factor could 
be used.  For example, in lethality studies, the exposure to irritant chemicals producing lung 
edema may have very similar dose-response slopes because the basic loss of cellular integrity 
at high doses is not a phenomenon that would be very different from one species to another. 
The available analyses supporting use of the 10-fold interspecies uncertainty factor were 
conducted on studies of toxicity by the oral route of administration. Further analysis of 
available data on chemicals for which there is both human and animal data for the same 
endpoints, and by the inhalation route of exposure  is warranted.  In addition, the existing 
analyses are limited in terms of toxicological endpoints examined.  Interspecies variability may 
differ significantly for different toxicological endpoints.  This is another area where research is 
needed. 
•	  The uncertainty factor typically used to account for intraspecies (interindividual) variability in 
the human population is 10. Interindividual variability has been recently modeled indicating a 
distribution that ranges from 1 to 720 for a specified set of chemicals (Gillis et al., 1997).  The 
value of 10 represented the 85
th percentile in this analysis. Further research into the factors 
contributing to interindividual variability, better characterization of sensitive subpopulations, 
and endpoints characterized by large interindividual variability is warranted.  Furthermore, the 
degree of protection of infants and children, a sensitive subpopulation by virtue of both 
increased exposure and potential increased susceptibility, afforded by a 10-fold interindividual 
uncertainty factor needs more research. 
•	  We have used time extrapolation with a modified Haber’s Law to extrapolate from the 
experimental duration in the acute study to an equivalent concentration for a one-hour 
exposure. There are empirical data for the value of n in Haber’s equation for some chemicals. 
More data would be valuable for additional chemicals.  Further analysis of the validity of the 
Haber’s Law application for different toxicological endpoints such as irritation would also be 
useful. 
•	  We currently use an additive approach to assessing the impacts of multiple chemicals on a 
target organ.  Some interactions may be synergistic and others antagonistic.  There is a need 
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for key studies on the additivity or synergism of chemicals that act on the same target organ. 
Further literature evaluation would also be helpful to elucidate whether the additive approach 
is the most valid approach. 
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Table A-1.  Acute Reference Exposure Levels (RELs), Averaging Times,
 and Toxicologic Endpoints 
Chemical Name (CAS #)  REL 
(mg/m
3) 
Avg 
time 
(h) 
Sp.
1  Toxicologic Endpoints  Severity
2 
Acrolein (107-02-8)  1.9 x 10
-1  1  H  Eye Irritation  Mild 
Acrylic Acid (79-10-7)  6 x 10
3  1  R  Respiratory Irritation  Mild 
Ammonia (7664-41-7)  3.2 x 10
3  1  H  Eye and Respiratory Irritation  Mild 
Arsenic and Inorganic Arsenic 
Compounds 
1.9 x 10
-1  4  M  Reproductive/Developmental  Severe 
Arsine (7784-42-1)  1.6 x 10
2  1  M  Hematologic System  Severe 
Benzene (71-43-2)  1.3 x 10
3  6  R  Reproductive/developmental  Severe 
Benzyl Chloride (100-44-7)  2.4 x 10
2  1  M& 
R 
Eye and Respiratory Irritation  Mild 
Carbon Disulfide (75-15-0)  6.2 x 10
3  6  R  Reproductive/Developmental  Severe 
Carbon Monoxide
3 (630-08-0)  2.3 x 10
4  1  H  Cardiovascular System  Mild 
Carbon Tetrachloride (56-23-5)  1.9 x 10
3  7  R  Reproductive/Developmental  Severe 
Chlorine (7782-50-5)  2.1 x 10
2  1  H  Respiratory Irritation  Mild 
Chloroform (67-66-3)  1.5 x 10
2  7  R  Reproductive/Developmental  Severe 
Chloropicrin (76-06-2)  2.9 x 10
1  1  M  Eye and Respiratory Irritation  Mild 
Copper and Compounds  1 x 10
2  1  H  Respiratory Irritation  Mild 
1,4-Dioxane (123-91-1)  3 x 10
3  1  H  Eye and Respiratory Irritation  Mild 
Epichlorohydrin (106-89-8)  1.3 x 10
3  1  H  Eye and Respiratory Irritation  Mild 
Ethylene Glycol Monobutyl 
Ether (111-76-2) 
1.4 x 10
4  1  H  Eye and Respiratory Irritation  Mild 
Ethylene Glycol Monoethyl 
Ether (110-80-5) 
3.7 x 10
2  6  R  Reproductive/Developmental  Severe 
Ethylene Glycol Monoethyl 
Ether Acetate (111-15-9) 
1.4 x 10
2  6  Rb  Reproductive/Developmental  Severe 
Ethylene Glycol Monomethyl 
Ether (109-86-4) 
9.3 x 10
1  6  R  Reproductive/Developmental  Severe 
Formaldehyde (50-00-0)  9.4 x 10
1  1  H  Eye Irritation  Mild 
Hydrogen chloride (7647-01-0)  2.1 x 10
3  1  H  Eye and Respiratory Irritation  Mild 
Hydrogen Cyanide (74-90-8)  3.4 x 10
2  1  Mk  CNS
4 - serious  Severe 
Hydrogen Fluoride (7664-39-3)  2.4 x 10
2  1  H  Eye and Respiratory Irritation  Mild 
Hydrogen Selenide  5 x 10
0  1  GP  Eye and Respiratory Irritation  Mild 
Hydrogen Sulfide (7783-06-4)
3  4.2 x 10
1  1  H  Respiratory Irritation  Mild 
Isopropyl Alcohol (67-63-0)  3.2 x 10
3  1  H  Eye and Respiratory Irritation  Mild 
Mercury (Inorganic) 
(7439-97-6) 
1.8 x 10
0  1  R  Reproductive/Developmental  Severe 
Methanol (67-56-1)  2.8 x 10
4  1  H  CNS
4 - mild  Mild 
Methyl Bromide (74-83-9)  3.9 x 10
3  1  H  CNS- mild (anorexia, nausea, 
headache; 
Mild 
Methyl Chloroform (71-55-6)  6.8 x 10
4  1  H  CNS - mild  Mild 
Methyl Ethyl Ketone (78-93-3)  1.3 x 10
4  1  H  Eye and Respiratory Irritation  Mild 
Methylene Chloride (75-9-2)  1.4 x 10
4  1  H  CNS - mild  Mild 
A - 2
   
Determination of Acute Reference Exposure Levels for Airborne Toxicants 
March 1999 
Chemical Name (CAS #)  REL 
(mg/m
3) 
Avg 
time 
(h) 
Sp.
1  Toxicologic Endpoints  Severity
2 
Nickel and Nickel Compounds  6 x 10
0  1  H  Respiratory Irritation; Immune 
Response 
Mild 
Nitric Acid (7697-37-2)  8.6 x 10
1  1  H  Respiratory Irritation  Mild 
Nitrogen Dioxide
3 
(10102-44-0) 
4.7 x 10
2  1  H  Respiratory Irritation  Mild 
Ozone
3 (10028-15-6)  1.8 x 10
2  1  H  Eye and Respiratory Irritation  Mild 
Perchloroethylene (127-18-4)  2 x 10
4  1  H  CNS - mild; Eye and Respiratory 
Irritation 
Mild 
Phenol (108-95-2)  5.8 x 10
3  1  H  Eye and Respiratory Irritation  Mild 
Phosgene (75-44-5)  4 x 10
0  1  R  Respiratory Irritation  Mild 
Propylene Oxide (75-56-9)  3.1 x 10
3  1  M  Eye and Respiratory Irritation  Mild 
Sodium Hydroxide (1310-93-2)  8 x 10
0  1  H  Skin, Eye, and Respiratory 
Irritation 
Mild 
Styrene (100-42-5)  2.1 x 10
4  1  H  Eye and Respiratory Irritation  Mild 
Sulfates
3  1.2 x 10
2  1  H  Respiratory Irritation  Mild 
Sulfur Dioxide
3
 (7446-09-5) 
6.6 x 10
2  1  H  Respiratory Irritation  Mild 
Sulfuric Acid and Oleum  1.2 x 10
2  1  H  Respiratory Irritation  Mild 
Toluene (108-88-3)  3.7 x 10
4  1  H  CNS - mild; 
Eye and Respiratory Irritation 
Mild 
Triethylamine (121-44-8)  2.8 x 10
3  1  H  CNS - mild; Eye Irritation  Mild 
Vanadium Pentoxide 
(1314-62-1) 
3 x 10
1  1  H  Respiratory Irritation  Mild 
Vinyl Chloride (75-01-4)  1.8 x 10
5  1  H  CNS - mild; Eye and Respiratory 
Irritation 
Mild 
Xylenes (m,o,p-isomers)  2.2 x 10
4  1  H  Eye and Respiratory Irritation  Mild 
1 Species used in key study for REL development: D = dog; GP = guinea pig: H = human;
            M = mouse; Mk = monkey; R = rat; Rb = rabbit 
2 Refers to effect severity levels-- see Hazard Identification section of main text or Table 6 
3 California Ambient Air Quality Standard 
4 CNS = Central Nervous System. 
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Table A-2. Hazard Index Target Organs 
Chemical Name (CAS #)  Target Organs 
Acrolein (107-02-8)  Respiratory System; Eye 
Acrylic Acid (79-10-7)  Respiratory System; Eye 
Ammonia (7664-41-7)  Respiratory System; Eye 
Arsenic and Inorganic Arsenic 
Compounds 
Reproductive/Developmental 
Arsine (7784-42-1)  Hematologic System 
Benzene (71-43-2)  Reproductive/developmental; Immune System; 
Hematologic System; 
Benzyl Chloride (100-44-7)  Respiratory System; Eye 
Carbon Disulfide (75-15-0)  Reproductive/Developmental; Nervous System 
Carbon Monoxide (630-08-0)  Cardiovascular System 
Carbon Tetrachloride (56-23-5)  Reproductive/Developmental; Nervous System; 
Alimentary Tract 
Chlorine (7782-50-5)  Respiratory System; Eye 
Chloroform (67-66-3)  Nervous System; 
Reproductive/Developmental 
Chloropicrin (76-06-2)  Respiratory System; Eye 
Copper and Compounds  Respiratory System 
1,4-Dioxane (123-91-1)  Respiratory System; Eye 
Epichlorohydrin (106-89-8)  Respiratory System; Eye 
Ethylene Glycol Monobutyl 
Ether (111-76-2) 
Respiratory System; Eye 
Ethylene Glycol Monoethyl 
Ether (110-80-5) 
Reproductive/Developmental 
Ethylene Glycol Monoethyl 
Ether Acetate (111-15-9) 
Reproductive/Developmental; Nervous System 
Ethylene Glycol Monomethyl 
Ether (109-86-4) 
Reproductive/Developmental 
Formaldehyde (50-00-0)  Eye; Respiratory System; Immune System 
Hydrogen Chloride (7647-01-0)  Respiratory System; Eye 
Hydrogen Cyanide (74-90-8)  Nervous System 
Hydrogen Fluoride (7664-39-3)  Respiratory System; Eye 
Hydrogen Sulfide (7783-06-4)  Headache and Nausea in Response to Odor 
Isopropyl Alcohol (67-63-0)  Respiratory System; Eye 
Mercury (Inorganic) 
(7439-97-6) 
Reproductive/Developmental 
Methanol (67-56-1)  Nervous System 
A - 4
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Chemical Name (CAS #)  Target Organs 
Methyl Bromide (74-83-9)  Nervous System; Respiratory Irritation; 
Reproductive/developmental 
Methyl Chloroform (71-55-6)  Nervous System 
Methyl Ethyl Ketone (78-93-3)  Respiratory System; Eye 
Methylene Chloride (75-9-2)  Nervous System 
Nickel and Nickel Compounds  Respiratory System; Immune System 
Nitric Acid (7697-37-2)  Respiratory System 
Nitrogen Dioxide 
(10102-44-0) 
Respiratory System 
Ozone (10028-15-6)  Eye; Respiratory System 
Perchloroethylene (127-18-4)  Nervous system; Eye; Respiratory System 
Phenol (108-95-2)  Respiratory System; Eye 
Phosgene (75-44-5)  Respiratory System 
Propylene Oxide (75-56-9)  Respiratory System; Eye; 
Reproductive/developmental 
Selenium: He2S  Respiratory System; Eye 
Sodium Hydroxide (1310-93-2)  Eye; Skin; Respiratory System 
Styrene (100-42-5)  Respiratory System; Eye; 
Sulfates  Respiratory System 
Sulfur Dioxide 
(7446-09-5) 
Respiratory System 
Sulfuric Acid and Oleum  Respiratory System 
Toluene (108-88-3)  Nervous System; Eye; Respiratory System; 
Reproductive/developmental?? 
Triethylamine (121-44-8)  Nervous System; Eye 
Vanadium Pentoxide 
(1314-62-1) 
Respiratory System; Eye 
Vinyl Chloride (75-01-4)  Nervous System; Eye; Respiratory System 
Xylenes (m,o,p-isomers)  Eye; Respiratory System 
A - 5
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Substances Listed Under the Air Toxics Hot Spots Act 
for Which Emissions Must be Quantified 
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Substances for which Emissions Must Be Quantified
 75070  Acetaldehyde

 60355  Acetamide

 67641  Acetone

 75058  Acetonitrile

 98862  Acetophenone

 53963  2-Acetylaminofluorene [PAH-Derivative, POM]

 107028  Acrolein

 79061  Acrylamide

 79107  Acrylic acid

 107131  Acrylonitrile

 107051  Allyl chloride

 7429905  Aluminum

 1344281  Aluminum oxide (fibrous forms)

 117793  2-Aminoanthraquinone [PAH-Derivative, POM]

 92671  4-Aminobiphenyl [POM]

 61825  Amitrole

 7664417  Ammonia

 6484522  Ammonium nitrate

 7783202  Ammonium sulfate

 62533  Aniline

 90040  o-Anisidine

 - Anthracene [PAH, POM], (see PAH)

 7440360  Antimony

 * 	 Antimony compounds

 including but not limited to:

 1309644  Antimony trioxide

 7440382  Arsenic

 1016 	 Arsenic compounds (inorganic)

 including but not limited to:

 7784421  Arsine

 1017  Arsenic compounds (other than inorganic)

 7440393  Barium

 * 	 Barium compounds

 - Benz[a]anthracene [PAH, POM], (see PAH)

 71432  Benzene

 92875  Benzidine (and its salts) [POM]

 1020 	 Benzidine-based dyes [POM]

 including but not limited to:

 1937377  Direct Black 38 [PAH-Derivative, POM]

 2602462  Direct Blue 6 [PAH-Derivative, POM]

 16071866  Direct Brown 95 (technical grade) [POM]

 -	 Benzo[a]pyrene [PAH, POM], (see PAH)
 -	 Benzo[b]fluoranthene [PAH, POM], (see PAH)

 271896 	 Benzofuran

 98077  Benzoic trichloride {Benzotrichloride}

 -	 Benzo[j]fluoranthene [PAH, POM], (see PAH)

 - Benzo[k]fluoranthene [PAH, POM], (see PAH)

 98884  Benzoyl chloride

 94360  Benzoyl peroxide

 100447  Benzyl chloride

 7440417  Beryllium

 * 	 Beryllium compounds

 92524  Biphenyl [POM]

 111444  Bis(2-chloroethyl) ether {DCEE}

 542881  Bis(chloromethyl) ether

 103231  Bis(2-ethylhexyl) adipate

 7726956  Bromine

 * 	 Bromine compounds (inorganic)

 including but not limited to:

 7758012  Potassium bromate

 75252  Bromoform

 106990  1,3-Butadiene

 141322  Butyl acrylate

 71363  n-Butyl alcohol

 78922  sec-Butyl alcohol

 75650  tert-Butyl alcohol

 85687  Butyl benzyl phthalate

 7440439  Cadmium

 *  Cadmium compounds

 156627  Calcium cyanamide

 105602  Caprolactam
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2425061  Captafol

 133062  Captan

 63252  Carbaryl [PAH-Derivative, POM]

 1050  Carbon black extracts

 75150  Carbon disulfide

 56235  Carbon tetrachloride

 463581  Carbonyl sulfide

 1055  Carrageenan (degraded)

 120809  Catechol

 133904  Chloramben

 56757  Chloramphenicol

 57749  Chlordane

 108171262  Chlorinated paraffins (average chain length, C12;

 approximately 60% chlorine by weight)

 7782505  Chlorine

 10049044  Chlorine dioxide

 79118  Chloroacetic acid

 532274  2-Chloroacetophenone

 1058  Chlorobenzenes

 including but not limited to:

 108907  Chlorobenzene

 25321226  Dichlorobenzenes (mixed isomers)

 including:

 95501  1,2-Dichlorobenzene

 541731  1,3-Dichlorobenzene

 106467  p-Dichlorobenzene {1,4-Dichlorobenzene}

 120821  1,2,4-Trichlorobenzene

 510156  Chlorobenzilate [POM] {Ethyl-4,4'­
dichlorobenzilate}

 13909096  1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1­
nitrosourea {Methyl CCNU}

 67663  Chloroform

 107302  Chloromethyl methyl ether (technical grade)

 1060  Chlorophenols

 including but not limited to:

 120832  2,4-Dichlorophenol

 87865  Pentachlorophenol

 95954  2,4,5-Trichlorophenol

 88062  2,4,6-Trichlorophenol

 95830  4-Chloro-o-phenylenediamine

 76062  Chloropicrin

 126998  Chloroprene

 95692  p-Chloro-o-toluidine

 7440473  Chromium
 *  Chromium compounds (other than hexavalent)

 18540299  Chromium, hexavalent (and compounds)

 including but not limited to:

 10294403  Barium chromate

 13765190  Calcium chromate

 1333820  Chromium trioxide

 7758976  Lead chromate

 10588019  Sodium dichromate

 7789062  Strontium chromate

 - Chrysene [PAH, POM], (see PAH)

 7440484  Cobalt

 *  Cobalt compounds

 1066  Coke oven emissions

 7440508  Copper

 *  Copper compounds

 1070  Creosotes

 120718  p-Cresidine

 1319773  Cresols (mixtures of) {Cresylic acid}

 including:

 108394  m-Cresol

 95487  o-Cresol

 106445  p-Cresol

 98828  Cumene

 80159  Cumene hydroperoxide

 135206 	 Cupferron

 1073  Cyanide compounds

 including but not limited to:

 74908  Hydrocyanic acid

 110827  Cyclohexane

 66819  Cycloheximide

 1163195  Decabromodiphenyl oxide [POM]

 1075 	 Dialkylnitrosamines

 including but not limited to:

 924163  N-Nitrosodi-n-butylamine

 1116547  N-Nitrosodiethanolamine

 55185  N-Nitrosodiethylamine

 62759  N-Nitrosodimethylamine
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621647  N-Nitrosodi-n-propylamine

 10595956  N-Nitrosomethylethylamine

 615054  2,4-Diaminoanisole

 1078  Diaminotoluenes (mixed isomers)

 including but not limited to:

 95807  2,4-Diaminotoluene {2,4-Toluenediamine}

 334883  Diazomethane

 226368  Dibenz[a,h]acridine [POM]

 224420  Dibenz[a,j]acridine [POM]

 - Dibenz[a,h]anthracene [PAH, POM], (see PAH)

 194592  7H-Dibenzo[c,g]carbazole

 - Dibenzo[a,e]pyrene [PAH, POM], (see PAH)

 - Dibenzo[a,h]pyrene [PAH, POM], (see PAH)

 - Dibenzo[a,i]pyrene [PAH, POM], (see PAH)

 - Dibenzo[a,l]pyrene [PAH, POM], (see PAH)

 132649  Dibenzofuran [POM]
 - Dibenzofurans (chlorinated)  (see Polychlorinated

 dibenzofurans) [POM]

 96128  1,2-Dibromo-3-chloropropane {DBCP}

 84742  Dibutyl phthalate

 - p-Dichlorobenzene {1,4-Dichlorobenzene}  (see

 Chlorobenzenes)

 91941  3,3'-Dichlorobenzidine [POM]

 72559  Dichlorodiphenyldichloroethylene {DDE} [POM]

 75343  1,1-Dichloroethane {Ethylidene dichloride}

 94757  Dichlorophenoxyacetic acid, salts and esters

 {2,4-D}

 78875  1,2-Dichloropropane {Propylene dichloride}

 542756  1,3-Dichloropropene

 62737  Dichlorovos {DDVP}

 115322  Dicofol [POM]

 - - Diesel engine exhaust

 9901  Diesel engine exhaust, particulate matter

 9902  Diesel engine exhaust, total organic gas

 #  Diesel fuel (marine)

 111422  Diethanolamine

 117817  Di(2-ethylhexyl) phthalate {DEHP}

 64675  Diethyl sulfate

 119904  3,3'-Dimethoxybenzidine [POM]

 60117  4-Dimethylaminoazobenzene [POM]

 121697  N,N-Dimethylaniline

 57976  7,12-Dimethylbenz[a]anthracene [PAH-Derivative,

 POM]

 119937  3,3'-Dimethylbenzidine {o-Tolidine} [POM]

 79447  Dimethyl carbamoyl chloride

 68122  Dimethyl formamide

 57147  1,1-Dimethylhydrazine

 131113  Dimethyl phthalate

 77781  Dimethyl sulfate

 534521  4,6-Dinitro-o-cresol (and salts)

 51285  2,4-Dinitrophenol

 42397648  1,6-Dinitropyrene [PAH-Derivative, POM]

 42397659  1,8-Dinitropyrene [PAH-Derivative, POM]

 25321146  Dinitrotoluenes (mixed isomers)

 including but not limited to:

 121142  ––2,4-Dinitrotoluene

 606202  ––2,6-Dinitrotoluene

 123911  1,4-Dioxane

 - Dioxins (Chlorinated dibenzodioxins) (see

 Polychlorinated dibenzo-p-dioxins) [POM]

 630933  Diphenylhydantoin [POM]

 122667  1,2-Diphenylhydrazine {Hydrazobenzene} [POM]

 1090  Environmental Tobacco Smoke

 106898  Epichlorohydrin

 106887  1,2-Epoxybutane

 1091  Epoxy resins

 140885  Ethyl acrylate

 100414  Ethyl benzene

 75003  Ethyl chloride {Chloroethane}

 - Ethyl-4,4'-dichlorobenzilate (see Chlorobenzilate)

 74851  Ethylene

 106934  Ethylene dibromide {1,2-Dibromoethane}

 107062  Ethylene dichloride {1,2-Dichloroethane}

 107211  Ethylene glycol

 151564  Ethyleneimine {Aziridine}

 75218  Ethylene oxide

 96457  Ethylene thiourea

 1101  Fluorides and compounds

 including but not limited to:

 7664393  Hydrogen fluoride

 1103  Fluorocarbons (brominated)
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1104  Fluorocarbons (chlorinated)

 including but not limited to:

 76131  Chlorinated fluorocarbon {CFC-113}

 50000  Formaldehyde

 - -	 Gasoline engine exhaust

 including but not limited to:

 - - Gasoline engine exhaust (condensates & extracts)

 9910  Gasoline engine exhaust, particulate matter

 9911  Gasoline engine exhaust, total organic gas

 1110  Gasoline vapors

 111308  Glutaraldehyde

 1115  Glycol ethers and their acetates

 including but not limited to:

 111466  Diethylene glycol

 111966  Diethylene glycol dimethyl ether

 112345  Diethylene glycol monobutyl ether

 111900  Diethylene glycol monoethyl ether

 111773  Diethylene glycol monomethyl ether

 25265718  Dipropylene glycol

 34590948  Dipropylene glycol monomethyl ether

 629141  Ethylene glycol diethyl ether

 110714  Ethylene glycol dimethyl ether

 111762  Ethylene glycol monobutyl ether

 110805  Ethylene glycol monoethyl ether

 111159  Ethylene glycol monoethyl ether acetate

 109864  Ethylene glycol monomethyl ether

 110496  Ethylene glycol monomethyl ether acetate

 2807309  Ethylene glycol monopropyl ether

 107982  Propylene glycol monomethyl ether

 108656  Propylene glycol monomethyl ether acetate

 112492  Triethylene glycol dimethyl ether

 126078  Griseofulvin

 76448  Heptachlor

 118741  Hexachlorobenzene

 87683  Hexachlorobutadiene

 1120  Hexachlorocyclohexanes

 including but not limited to:

 58899  Lindane

 77474  Hexachlorocyclopentadiene

 67721  Hexachloroethane

 680319  Hexamethylphosphoramide

 110543  Hexane

 302012  Hydrazine

 7647010  Hydrochloric acid

 -	 Hydrocyanic acid (see Cyanide compounds )

 7783064 	 Hydrogen sulfide

 123319  Hydroquinone

 - Indeno[1,2,3-cd]pyrene [PAH, POM], (see PAH)

 1125  Isocyanates

 including but not limited to:

 822060  Hexamethylene-1,6-diisocyanate

 101688  Methylene diphenyl diisocyanate {MDI} [POM]

 624839  Methyl isocyanate

 -	 Toluene-2,4-diisocyanate (see Toluene diisocyanates)

 - Toluene-2,6-diisocyanate (see Toluene diisocyanates)

 78591  Isophorone

 67630  Isopropyl alcohol

 80057  4,4'-Isopropylidenediphenol [POM]

 7439921 	 Lead

 1128  Lead compounds (inorganic)

 including but not limited to:

 301042  Lead acetate

 - Lead chromate (see Chromium, hexavalent)

 7446277  Lead phosphate

 1335326  Lead subacetate

 1129  Lead compounds (other than inorganic)

 108316  Maleic anhydride

 7439965  Manganese

 *  Manganese compounds

 7439976  Mercury

 * 	 Mercury compounds

 including but not limited to:

 7487947  Mercuric chloride

 593748 	 Methyl mercury {Dimethylmercury}

 67561  Methanol

 72435  Methoxychlor [POM]

 75558  2-Methylaziridine {1,2-Propyleneimine}

 74839  Methyl bromide {Bromomethane}

 74873  Methyl chloride {Chloromethane}

 71556  Methyl chloroform {1,1,1-Trichloroethane}

 56495  3-Methylcholanthrene [PAH-Derivative, POM]
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3697243  5-Methylchrysene [PAH-Derivative, POM]

 101144  4,4'-Methylene bis(2-chloroaniline) {MOCA} [POM]

 75092  Methylene chloride {Dichloromethane}

 101779  4,4'-Methylenedianiline (and its dichloride) [POM]

 78933  Methyl ethyl ketone {2-Butanone}

 60344  Methyl hydrazine

 74884  Methyl iodide {Iodomethane}

 108101  Methyl isobutyl ketone {Hexone}

 80626  Methyl methacrylate

 1634044  Methyl tert-butyl ether

 443481  Metronidazole

 90948  Michler's ketone [POM]

 1136  Mineral fibers (fine, manmade)

 (fine mineral fibers which are manmade and are

 airborne particles of a respirable size greater

 than 5 microns in length, less than or equal to

 3.5 microns in diameter, with a length to

 diameter ratio of 3:1)

 including but not limited to:

 1056  Ceramic fibers

 1111  Glasswool fibers

 1168  Rockwool fibers

 1181  Slagwool fibers

 1135  Mineral fibers (other than manmade)

 including but not limited to:

 1332214  Asbestos

 12510428  Erionite

 1190  Talc containing asbestiform fibers

 1313275  Molybdenum trioxide

 - Naphthalene [PAH, POM], (see PAH)

 7440020  Nickel

 * 	 Nickel compounds

 including but not limited to:

 373024  Nickel acetate

 3333393  Nickel carbonate

 13463393  Nickel carbonyl

 12054487  Nickel hydroxide

 1271289  Nickelocene

 1313991  Nickel oxide

 12035722  Nickel subsulfide

 1146  Nickel refinery dust from the pyrometallurgical

 process

 61574  Niridazole

 7697372  Nitric acid

 139139  Nitrilotriacetic acid

 98953  Nitrobenzene

 92933  4-Nitrobiphenyl [POM]

 7496028  6-Nitrochrysene [PAH-Derivative, POM]

 607578  2-Nitrofluorene [PAH-Derivative, POM]

 302705  Nitrogen mustard N-oxide

 100027  4-Nitrophenol

 79469  2-Nitropropane

 5522430  1-Nitropyrene [PAH-Derivative, POM]

 156105  p-Nitrosodiphenylamine [POM]

 684935  N-Nitroso-N-methylurea

 59892  N-Nitrosomorpholine

 100754  N-Nitrosopiperidine

 930552  N-Nitrosopyrrolidine

 - - PAHs (Polycyclic aromatic hydrocarbons) [POM]

 including but not limited to:

 1151  PAHs, total, w/o individ. components reported

 1150  PAHs, total, with individ. components also

 reported

 120127  Anthracene

 56553  Benz[a]anthracene

 50328  Benzo[a]pyrene

 205992  Benzo[b]fluoranthene

 205823  Benzo[j]fluoranthene

 207089  Benzo[k]fluoranthene

 218019  Chrysene

 53703  Dibenz[a,h]anthracene

 192654  Dibenzo[a,e]pyrene

 189640  Dibenzo[a,h]pyrene

 189559  Dibenzo[a,i]pyrene

 191300  Dibenzo[a,l]pyrene

 193395  Indeno[1,2,3-cd]pyrene

 91203 	 Naphthalene

 #  PAH-Derivatives (Polycyclic aromatic hydrocarbon

 derivatives) [POM]

 (including but not limited to those substances
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listed in Appendix A with the bracketed

 designation [PAH-Derivative, POM])

 56382  Parathion

 1336363  PCBs (Polychlorinated biphenyls) [POM]

 82688  Pentachloronitrobenzene {Quintobenzene}

 79210  Peracetic acid

 127184  Perchloroethylene {Tetrachloroethane}

 50066  Phenobarbital

 108952  Phenol

 106503  p-Phenylenediamine

 90437  2-Phenylphenol [POM]

 75445  Phosgene

 7723140  Phosphorus

 - - Phosphorus compounds:

 7803512  Phosphine

 7664382  Phosphoric acid

 10025873  Phosphorus oxychloride

 10026138  Phosphorus pentachloride

 1314563  Phosphorus pentoxide

 7719122  Phosphorus trichloride

 126738  Tributyl phosphate

 78400  Triethyl phosphine

 512561  Trimethyl phosphate

 78308  Triorthocresyl phosphate [POM]

 115866  Triphenyl phosphate [POM]

 101020  Triphenyl phosphite [POM]

 85449  Phthalic anhydride

 - -	 Polychlorinated dibenzo-p-dioxins {PCDDs or

 Dioxins} [POM]

 including but not limited to:

 1086  Dioxins, total, wo individ. isomers reported

 {PCDDs}

 1085  Dioxins, total, with individ. isomers also

 reported {PCDDs}

 1746016  2,3,7,8-Tetrachlorodibenzo-p-dioxin {TCDD} [POM]

 40321764  1,2,3,7,8-Pentachlorodibenzo-p-dioxin [POM]

 39227286  1,2,3,4,7,8-Hexachlorodibenzo-p-dioxin [POM]

 57653857  1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin [POM]

 19408743  1,2,3,7,8,9-Hexachlorodibenzo-p-dioxin [POM]

 35822469  1,2,3,4,6,7,8-Heptachlorodibenzo-p-dioxin [POM]

 - -	 Polychlorinated dibenzofurans {PCDFs or

 Dibenzofurans} [POM]

 including but not limited to:

 1080  Dibenzofurans (Polychlorinated dibenzofurans)

 {PCDFs} [POM]

 51207319  2,3,7,8-Tetrachlorodibenzofuran [POM]

 57117416  1,2,3,7,8-Pentachlorodibenzofuran [POM]

 57117314  2,3,4,7,8-Pentachlorodibenzofuran [POM]

 70648269  1,2,3,4,7,8-Hexachlorodibenzofuran [POM]

 57117449  1,2,3,6,7,8-Hexachlorodibenzofuran [POM]

 72918219  1,2,3,7,8,9-Hexachlorodibenzofuran [POM]

 60851345  2,3,4,6,7,8-Hexachlorodibenzofuran [POM]

 67562394  1,2,3,4,6,7,8-Heptachlorodibenzofuran [POM]

 55673897  1,2,3,4,7,8,9-Heptachlorodibenzofuran [POM]

 #  POM (Polycyclic organic matter)

 (including but not limited to those substances

 listed in Appendix A with the bracketed

 designation of [POM], [PAH, POM], or

 [PAH-Derivative, POM])

 57830  Progesterone

 1120714  1,3-Propane sultone

 57578  beta-Propiolactone

 123386  Propionaldehyde

 114261  Propoxur {Baygon}

 115071  Propylene

 75569  Propylene oxide

 - 1,2-Propyleneimine (see 2-Methylaziridine)

 110861  Pyridine

 91225  Quinoline

 106514  Quinone

 1165  Radionuclides

 including but not limited to:

 24267569  Iodine-131

 1166  Radon and its decay products

 50555  Reserpine [POM]

 #  Residual (heavy) fuel oils

 7782492  Selenium

 * 	 Selenium compounds

 including but not limited to:

 7446346 	 Selenium sulfide

 1175  Silica, crystalline
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7440224  Silver

 *  Silver compounds

 1310732  Sodium hydroxide

 100425  Styrene

 96093  Styrene oxide

 7664939  Sulfuric acid

 100210  Terephthalic acid

 79345  1,1,2,2-Tetrachloroethane

 7440280  Thallium

 *  Thallium compounds

 62555  Thioacetamide

 62566  Thiourea

 7550450 	 Titanium tetrachloride

 108883  Toluene

 - 2,4-Toluenediamine (see 2,4-Diaminotoluene)

 1204  Toluene diisocyanates

 including but not limited to:

 584849  Toluene-2,4-diisocyanate

 91087  Toluene-2,6-diisocyanate

 95534  o-Toluidine

 8001352 	 Toxaphene {Polychlorinated camphenes}

 79005  1,1,2-Trichloroethane {Vinyl trichloride}

 - 1,1,1-Trichloroethane (see Methyl chloroform)

 79016  Trichloroethylene

 - 2,4,6-Trichlorophenol (see Chlorophenols)

 121448  Triethylamine

 1582098  Trifluralin

 95636  1,2,4-Trimethylbenzene

 540841  2,2,4-Trimethylpentane

 51796  Urethane {Ethyl carbamate}

 7440622  Vanadium (fume or dust)

 108054  Vinyl acetate

 593602  Vinyl bromide

 75014  Vinyl chloride

 75354  Vinylidene chloride

 1206  Wood preservatives (containing arsenic and

 1210  Xylenes (mixed xylenes)

 including:

 108383  m-Xylene

 95476  o-Xylene

 106423  p-Xylene

 7440666  Zinc

 *  Zinc compounds

 including but not limited to:

 1314132  Zinc oxide
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